










































































There# is# an# everIgrowing# need# for# a# transition# from# the# flat# world# of# 2D#
monolayer# cell# culture# to# one# of# 3D# organotypic# tissue# structures,# bringing#
increased# physiological# relevance# to# early# benchItop# scientific# discoveries.# # The#
development#of# simple#methods# for#3D#cell# culture# is# essential# to#gain#acceptance#
among# researchers# and# industry.# # This# dissertation# presents# a# novel# glass#
micromold# that#allows#optimal#engineering#of# cells# into#a#3D#cell# spheroid.# #When#
cells# are# loaded# onto# the# micromold,# they# settle# into# microIwells,# conicalIshaped#
recesses,# and# are# cultured# for# several# days# until# a# cell# aggregate# has# formed.# # In#
diabetes,# islets# are# dispersed# into# single# cells,# loaded# onto# the# micromold,# and#
engineered# into# isletIlike# spheroids# called#Kanslets.# # Native# islets# exist# in# a# broad#
size# range# (50# to# 400# μm# in# diameter)# and# inherently# contain# various# sizeI
dependent# limitations.# # To# overcome# these# barriers,# Kanslets# are# limited# to# a#
uniform#size#range#(diameter#<#125#μm)#during#cell#reaggregation.# #While#Kanslets#
are# organotypic# spheroids# that# mimic# the# structure# and# function# of# native# islets,#
they#have#a#superior#viability#and#a#decreased#diffusion#barrier.##These#qualities#are#
essential# for#drug# testing#and# islet# transplantation,#where#diffusion# is# the#primary#
mode#of#nutrient#transport.##Diabetic#rats#that#received#Kanslet#transplants#regained#
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What#began#as#a#project# to#engineer#optimal# islet# tissue# for# transplantation#
for# the# treatment#of# type#1#diabetes,# transformed# into# the# invention#of# a#platform#
technology# for#producing#3D#cell# clusters.# #The# innovations#within# this# technology#
enable# the# production# of# various# 3D# cell# spheroids# with# applications# in# drug#
discovery,# regenerative#medicine,# and# a# variety# of# other# fields.# # This# dissertation#
focuses# on# using# this# technology# in# diabetes# and# provides# an# exploration# into#
various#future#applications.##
The#overall#objective#of#this#dissertation#was#to#engineer#optimal#islets#using#





In#accomplishing# these#goals,# I#developed#a#device#on#which#dispersed# islet#
cells#could#be#optimally#reaggregated#into#3D#isletIlike#cell#clusters.##I#then#examined#
whether# these# engineered# islets# provide# a# physiologically# relevant# model# for#
diabetes# that#overcame#several#of# the#barriers# that#hamper# the#use#of# islets# in# the#
clinic.# # In# addition# to# the# original# goal,# I# explored# the# basic# application# of# this#
technology#as#a#platform#in#various#fields#for#future#development.#
Chapter# 2# provides# a# detailed# background# of# pharmaceutical# drug#
development#and# the#current#methods#used# to# find#new#molecular#entities,#with#a#
discussion#about# their#advantages#and#disadvantages.# # In# focusing#on#diabetes,#we#
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identify# a# necessity# for#more# suitable# technologies# in# the# diabetes# drug# discovery#
market.#
Chapter# 3# provides# support# for# the# necessity# to# engineer# islet# cell# clusters#
and#presents#the#development#of#a#novel#technology#for#3D#cell#culture.##This#novel#
technology#begins#with#the#development#and#fabrication#of#a#micromold#device#for#
the# optimal# reaggregation# of# dispersed,# single# islet# cells# into# 3D# isletIlike# cell#
clusters,#or#Kanslets.##I#examine#the#feasibility#of#the#technology#for#commercial#use#
and#high#throughput#drug#screening.#
In# chapter# 4,# Kanslets,# one# of# the# resulting# 3D# cell# structures,# are#
characterized#and#compared#to#isolated,#native#islets.##Cell#viability,#glucose#diffusion#
and#uptake,# composition,#morphology,#and# function#are#among# the#various# factors#
characterized.# #A#comparison#to#native#islets#provides#the#rational#for#utilization#of#
Kanslets# as# an# alternative# for# drug# discovery# and# transplantation.# # For# its#

















Researchers# are# increasingly# embracing# the# transition# from# the# traditional,#
flat#world#of#2D#cell#culture#to#the#organotypic#nature#of#3D#tissue#culture.##These#3D#
tissue#spheroids#provide#a#more#physiologically#relevant#model#for#studying#various#
diseases.# # Cancer# researchers# have# already# begun# the# change# to# in# vitro# tumor#



















compounds#with# the# high# probability# of# finding# the#most# valuable# and# successful#
hits.# # As# innovative# technologies# and# techniques# are# being# developed,# the# recent#
trend# in# drug# discovery# and# highIthroughput# screening# (HTS)# is# a# paradigm# shift#
from# twoIdimensional# (2D)# to# threeIdimensional# (3D)# cell# culture.# # Emphasis# is#
being#placed#on#more#physiologically#relevant#models#for#use#in#drug#discovery#and#
development.# # This# relevance# comes# through# transition# from# a# traditional# 2D#
monolayer# cell# culture,# to# a# multicellular,# organotypic# 3D# cell# structure.# # The#
pharmaceutical#industry#primarily#utilizes#2D#assay#technologies#that#tend#to#be#less#
accurate# and# often# times# do# not# predict# in# vivo# outcomes.# # Ultimately# leading# to#
longer# drug# development# timelines,# increased# failure# rates,# and# increased# costs.##
The#utilization#of#3D#cell# cultures#offers#a#model# that#better#mimics# the#natural# in#
vivo#structure#and#function#of#native#tissues,#yielding#stronger#correlations#between#
in#vitro,#cellIbased#experimentation#and#subsequent#in#vivo#responses.##Transitioning#





complex# (Figure# 2.1),# but# it# can# be# consolidated# into# 3# major# stages:# discovery,#
preclinical,# and# clinical# [1].# A# discovery# phase# generally# involves# target#
identification#and#validation,#assay#development,#screening,#and#lead#identification.##
Once#suitable#drug#compounds#(leads)#are#identified,#they#are#subject#to#extensive#in#
vitro# testing# (lead# optimization)# and# animal# model# testing# during# the# preclinical#
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development# (R&D)# are#placed#behind# these# assays,# as# they# are# critical# in# finding#
high#quality#hits.# #Further#assaying#and#discovery#narrows# the# list#of#hits# to#a#key#
selection# of# high# quality# lead# compounds.# # More# money# and# time# is# invested# in#
optimizing#these#leads#and#developing#them#into#the#pharmaceuticals#that#will#enter#
preclinical# and# clinical# trials.# #The# complexities# and# intricacies# involved#with#each#
stage#can#easily#generate#problems#that# increase#development# time#and#costs,#and#
may#even#lead#to#failure#and#removal#from#the#market.##





cost# is#due#to# the#high#attrition#of#NMEs#that# fail#during#development,#particularly#
during# later# stages# including# Phase# II# and# Phase# III# clinical# trials,# accounting# for#
roughly#75%#of#the#total#costs#[4I10].# #According#to#a#recent#report,#in#2011#alone,#




The#20Iyear# life# span#of# a#utility#patent# from# initial# application#means# that# a# long#
development# time# leaves# little# room# to# generate# revenue—let# alone,# enough#
revenue# to# recover# the# cost# of#R&D.# # Although# resources# and# effort# are# being#put#





of# NMEs# before# they# enter# further# development.# # There# are# several# methods# of#
discovery#including#molecules#from#natural#products,#repositioning#of#drugs#on#the#
market,#rational#drug#design,#and#combinatorial#chemistry.##If#the#initial#candidates#







One# of# the# oldest# and# most# successful# methods# to# find# new# drugs# has# been# the#
utilization# of# natural# products# or# natural# productIderived# compounds,# and#
continues#to#play#a#major#role#as#a#novel#lead#generator#[12I17].# #Natural#products#
are#found#in#plants,# insects,#reptiles,#marine#life,#microogranisms,#and#a#number#of#
other# sources.# # These# compounds# have# produced# some# of# the# world’s# most# well#
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known#drugs#including#aspirin,#caffeine,#penicillin,#tetracycline,#paclitaxel—and#the#
list# continues# [13,14,18].# # Paclitaxel,# sold# by# BristolIMyers# Squibb# as# Taxol,# a#
compound#from#the#bark#of#the#Pacific#yew#tree,#Taxus#brevifolia,#was#discovered#to#
have# anticancer# activity# and# is# currently# used# as# a# chemotherapy# against# lung,#
ovarian,#breast,#head#and#neck#cancers#[19].##Natural#sources#are#highly#soughtIafter#





of# existing# drugs# and# therapies# into# new# markets# or# for# new# indications.##
Repositioning# allows# for# a# quicker# time# to# market# with# reduced# risks# [2,20,21].##
There# are# several#ways# that# drug# repositioning# can# occur.# # As# patients# use# drugs#
available# on# the# market,# physicians# and# scientists# continue# to# gather# data,#
sometimes# providing# support# for# a# new# indication# as# opposed# to# its# original#
intended#use.# #Additionally,#during#clinical#trials,#it#may#be#found#that#a#drug#is#not#
effective# for# its# intended# target# indication,# but# shows# benefit# for# a# different#
indication.# # Drugs# repositioned# during# clinical# trials# come#with# support# from# the#
extensive# amounts# of# gathered# data# about# efficacy,# pharmacokinetics,# toxicology,#






Filing# additional# methodIofIuse# patents# is# often# required# to# solidify#






Rational# drug# design# was# initially# hailed# as# the# answer# to# the# challenges#
associated# with# drug# discovery.# # This# approach# involves# the# creation# of# a# small#
molecule#to#act#on#specific#biological#target#based#on#the#current#knowledge#of#the#
target#and#desired#therapeutic#effects.##The#basic#idea#is#to#construct#an#appropriate#
ligand# (small# molecule)# that# will# bind# to# a# target# to# produce# a# “drugIlike”# effect.##
This#approach#to#drug#development# is#often# times#computerIassisted#and# involves#
knowledge#of#the#3D#structure#and#function#at#the#biomolecular#level#of#the#target,#
known#as#structure#guidedIcomputer#aided#drug#design#[22].# #Although#this#can#be#








To# date,# the# Food# and# Drug# Administration# (FDA)# has# only# approved# one#
compound# for# clinical# use# that# was# discovered# through# combinatorial# chemistry,#
while# many# remain# in# various# stages# of# development.# # In# 2005,# Sorafenib# was#





for# discovery,# it# increases# the# probability# of# finding# new# and# unique# compounds,#
and#can#be#equated#to#finding#a#needle#in#a#haystack#[17].##These#active#compounds#
may# provide# increased# efficacy,# decreased# toxicity,# or# provide# a# different#
mechanism# of# action# in# comparison# to# an# original# drugIlike# molecule.##
Combinatorial#chemistry#provides#another#method#of#rational#design#in#developing#
NMEs.#
In# general,# drug# discovery# aims# to# identify# the# candidate# molecules# that#
produce# a# therapeutic# effect.# # In# all# these# methods# of# discovery,# there# is# one#
common# goal:# finding# NMEs# that# will# successfully# become# marketable#
pharmaceutical#drugs.# #More# importantly,# this#goal#must#be# completed# in#a# timely#








In# identifying# lead# compounds# on# which# to# focus# R&D# efforts,# the#
pharmaceutical# industry# is# increasingly#utilizing#highIthroughput# screening# (HTS).##
HTS#allows#screening#of# large# libraries#of#chemical#compounds#to#search# for# those#
that# have# an# effect# on# a# target.# # Over# the# last# few# decades,# HTS# capacities# have#










technology# has# lead# to# significant# timesaving# during# discovery# and# a# 10Ifold#
reduction#in#testing#costs#[25,26].#Few#argue#that#even#with#these#benefits#and#the#
significant# capital# that# has# been# invested# in#HTS# to# date,# it# has# achieved#minimal#
success#[21,26,27].#
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The# basic# foundation# of# HTS# relies# on# a# large# compound# library.# # These#
libraries#are#built#though#the#utilization#of#one#or#more#of#the#previously#discussed#
methods# of# drug# discovery.# # In# combination# with# HTS,# sampling# thousands# of#
compounds# against# a# target# significantly# reduces# the# time# required# to# find# lead#
compounds.# # A# typical# screen#may# consist# of# 100,000# samples# and# yield# between#
100#to#500#primary#hits#[17].##Compound#libraries,#are#the#core#of#HTS,#consisting#of#
several# thousand# to# over# a# million# individual# compounds.# # These# libraries# are#





positives# demands# the# development# of# more# accurate# and# reliable# screening#
technologies#[28].#
In# conducting# a# highIthroughput# screen,# there# are# two# broad# categories# of#
assays# to# choose# from:# biochemical# assays# or# cellIbased# assays.# # Developed# and#
highly# utilized# in# the# 1990s,# biochemical# assays# provide# a# direct# approach# in#
determining#compound#activity#on#an#isolated#target#of#interest#[29,30].##This#assay#
provides# targetIbased# assessment# of# biochemical# interactions# such# as# enzymatic#






To# warrant# the# capital# investment# in# HTS# technology,# emphasis# must# be#
placed#in#using#methods#that#will#provide#the#highest#success#rate.##The#introduction#
of#cellIbased#assays#accommodates#for#observing#the#effects#of#compounds#directly#
on# biological# systems.# # The# current# use# of# 2D# cellIbased# HTS# technologies# as# a#
primary#tool#for#screening#large#compound#libraries#aims#to#produce#higher#quality#
data# [31I33].# # Compounds# are# tested# on# cells# to# account# for# complex# biological#
processes.# #Many#of#these#technologies#have#a#proven#track#record#for#a#quick#and#
lowIcost# method# to# discover# potential# drug# candidates,# with# many# discoveries#
currently#in#the#development#pipeline.##In#most#cases,#the#direct#target#on#which#the#
test# compounds# act# upon# is# unknown;# instead# hits# occur# due# to# complex# cellular#
pathways# [29].# # In# a# primary# screening,# a# wellIestablished# cell# line# is# dispensed,#
using#automated#equipment,#in#a#flat#(2D)#monolayer#on#the#bottoms#of#96I,#384I,#or#
1536Iwell#plates.# #Cells#are#subject#to#compounds#and#assayed#for#effects#including#
metabolism,# proliferation,# cytotoxicity,# or# function.# # After# a# list# of# potential#
compounds#is#narrowed,#a#secondary#screen#is#conducted#to#further#determine#the#
most#viable#leads.#
There# are# many# advantages# to# cellIbased# assay# technologies# compared# to#
biochemical# assays.# # A# cellIbased# assay# provides# a# more# physiologically# relevant#
platform# enabling# living# cells# to# be# assayed# after# direct# exposure# to# drug#
compounds.# # In# this# environment,# it# is# possible# to# discover#NMEs# for# a# variety# of#
pharmacological# effects.# # The# complexities# of# intercellular# activity# allow# the#
discovery# for# either# agonists# or# antagonists# [34].# # Drugs# can# act# along# various#
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chemical#pathways#within#a# cell,# leading# to#a# true#phenotypic# screening#approach.##
The#researcher#knows#the#end#effect#measured#in#the#cell,#but#may#have#no#concept#
of#the#mechanism#of#action#with#the#primary#screen.##They#may#set#off#a#cascade#of#
responses# within# a# cell# that# may# or# may# not# have# a# beneficial# effect,# and# allows#
identification# early# in# the# discovery# process.# # This# is# akin# to# how# medicinal#




Although#2D# cellIbased# assays# provide# a# simplified#primary# screening# tool,#
they# lack#several#key#essentials#necessary#to#accurately#and#predictably#determine#
the#best#candidates[36].##A#large#number#of#false#positives#and#false#negatives#can#be#
mixed# among# the# vast# amount# of# data# and# requires# scrutinizing# true# hits# versus#
artifacts#[34].##Additionally,#compounds#that#show#little#or#no#effect#during#HTS#may#
truly#be#potentially#beneficial#drugs#if#they#were#moved#forward#into#clinical#trials.##
During# lead# optimization,# several# cellIbased# assays# are# conducted# concurrently# to#
further# characterize# and# develop# features# such# as# efficacy,# potency,# safety,# and#
selectivity# [34].# # Lead# optimization# is# an# essential# step# in# the# pathway# of# drug#
development# success.# # Studies# using# an# unsuitable# lead# means# time,# money# and#
resources#may#be#spent#on#products#that#end#up#failing.##As#mentioned#previously,#a#




development# times,# greater# expenditure,# and#high# attrition# rates# that# plague#drug#
development.#
An# examination# of# the# drug# discovery# process# demonstrates# various#
inconsistencies# that#can#be# traced#back#to# the# limitations#of#using#2D#cultured#cell#




vitro# environment,# they# must# often# be# genetically# manipulated# to# support#
proliferation# and#maintain# a# differentiated# state.# # This# cancerIlike# transformation#
enables#stable#cell#expansion#through#passaging,#creating#an#immortalized#cell#line.##
Immortalized# cell# lines# can# be# proliferated# indefinitely# without# changes# to# their#
functionality#as#compared#to#primary#cells.##Cell#transformation#can#have#advantages#
including#revealing#the#effects#of#genetic#manipulation#and#the#reproducibility#of#a#
specific# batch# of# cells.# Unfortunately,# these# genetic# modifications# change# cell#
phenotype#over#time,#producing#new#abnormalities,#and#lead#to#alterations#or#loss#of#
native#functions#and#responses,#ultimately#affecting#in#vitro#testing#[37].##




altered# phenotype,# the# mere# fact# that# the# cells# are# in# a# 2D# state# affects# study#
outcomes.##In#the#last#decade,#extensive#amounts#of#research#have#shown#that#cells#
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cultured# in#a#2D#environment# lack#efficacy# in#predicting# in# vivo# responses# in#a#3D#
environment#and#may#exhibit#unnatural# characteristics# [38I48].# #Within#our#body,#
cells# exist# in# a# complex# threeIdimensional# environment# that# provides# support# for#
cellItoIcell# communication,# mechanical# stimulation,# and# biochemical# signaling,#
among#a#number#of# factors# that#play#a#critical#role#at# the#cellular,# tissue,#and#even#
organ#level.#




monolayers# of# the# same# cell# type# [49].# # Preclinical# animal# studies# are# the# current#
avenue# to# provide# the# best# prediction# of# in# vivo# responses# to# NMEs.# # Shifting#
paradigms#from#2D#to#3D#cell#culture,#will#not#only#provide#a#more#relevant#model#











Worldwide,# roughly# 350# million# individuals# are# affected# and# the# International#
Diabetes# Federation# estimates# its# prevalence# to# reach# 1# in# 10# by# 2030# [54].# # The#
United# States# faces# an# economic# burden# with# expenditure# and# lost# productivity#
totaling# $174# billion# [55].# # Diagnosed# individuals# spend# on# average# $11,744#
annually#on#healthcare#[55].#
The#hallmark#of#diabetes#is#the#body’s#inability#to#produce#or#utilize#insulin,#
leading# to# an# abnormal# maintenance# of# blood# glucose# levels.# # In# type# 1# (insulinI
dependent)# diabetes,# autoimmune# destruction# of# the# betaIcells# halt# production# of#
insulin.# # Type# 2# (insulinIresistant)# diabetes# is# caused# by# the# body’s# inability# to#
properly#utilize#insulin#and#accounts#of#nearly#90%#of#all#diabetes#cases.##Even#with#
the# availability# of# medications,# glucose# monitoring,# and# insulin# therapy,# chronic#
complications# include#kidney#failure,#blindness,#amputations,#and#even#death.# #The#
insulinIproducing# betaIcells# affected# by# diabetes# are# located# within# the# islets# of#
Langerhans.# # Islets# are# natural,# small# cell# clusters# scattered# throughout# the#
pancreas.# # They# play# an# essential# role# in# monitoring# blood# glucose# levels# and#
secreting# hormones# accordingly.# # Islets# are# composed# of# a# variety# of# hormoneI
producing# cell# types# including# glucagon# (alphaIcells),# insulin# (betaIcells),#
somatostatin# (deltaIcells),# and# pancreatic# polypeptide# (PPIcells).# # The# insulin#
producing#betaIcells#make#up#a#majority#of#the#islet#[56].#
The#challenges#associated#with#drug#discovery#for#those#working#in#the#field#
of# diabetes# have# been# immense.# # Insulin# injection# is# a# requirement# for# those#
suffering#from#type#1#diabetes#as#they#lack#insulin#production.##With#90%#of#diabetes#




$114# billion# by# 2016# [57].# # Type# 2# patients# often# require# oral# medications,#
sometimes# combined# with# insulin,# for# glucose# control.# # Current# major# types# of#
medications# include:# sulfonylureas,# meglitinides,# biguanides,# thiazolidinediones,#
DPPIinhibitors,# and# incretin#mimetics# (Table#2.1).# #Most#of# these#oral#medications#
act#by# increasing# insulin#output# from#islets,# increasing# insulin#sensitivity#on#target#
organs,# or#decreasing# glucose#uptake# into# the#blood# stream.# # The# side# effects# that#
accompany# some# of# these# drugs# can# include# severely# low# blood# glucose#




drugs# to# the#market?# # It# has# not# been# for# a# lack# of# trying,# but# rather# the# lack# of#
suitable# technologies.# # Current# screening#methods# for# diabetes# drugs# includes# 2D#




inherent# cellItoIcell# contact# present# within# intact# islets,# and# has# been# known# for#




This# provides# much# of# the# current# reasons# for# the# use# of# betaIcell# lines#
instead# of# primary# cells.# # In# order# for# betaIcells# to# maintain# insulin# secretion# in#
culture,# cells#are# transformed,#and#stable#cell# lines#are#created.# #BetaIcell# lines#are#
mainly#rodentIderived#from#insulinomas#generated#in#transgenic#mice#or#radiationI
treated# rat# cells,# and# only# a# few# cell# lines# exhibit# glucoseIsensitivity# [39,66,78].##
Genetic# manipulations# that# arise# when# transforming# the# cells# to# a# cancerIlike#
phenotype# can# also# raise# new# problems# including# the# accidental# destruction# of#
native#cell# functions.# #The#main#goal# in#creating#all#of#these#cell# lines# is#to#produce#
insulinIsecreting# cells# that# retain# similar# characteristics# to# betaIcells.# # The# use# of#
genetically#manipulated# cells#may# produce# new# issues,# especially# with# the# native#
functional#pathways#being#altered#[39,66].##For#instance,#the#transformed#betaIcells#
may# provide# insightful# knowledge# into# cellular#mechanisms# of# cancer# production,#
however#they#are#less#than#ideal#for#the#discovery#of#novel#compounds#for#standard#
diabetes#treatment.#
As# researchers# continue# to# focus# efforts# on# producing# novel# betaIcell# cell#
lines,# one# might# ask:# # what# about# the# other# cell# types# present# within# the# islet?##
Within#our#bodies,#islets#exist#as#a#cluster#of#various#cell#types.##Extensive#research#
supports#that#the#combined#presence#of#all#cell#types#within#an#islets#are#involved#in#
its# in# vitro# and# in# vivo# function# [68,69,71I73,79].# # Islets,# once# isolated# from# the#
pancreas,#are#used#extensively#in#research#and#transplantation.##Unfortunately,#this#
is#not#necessarily#the#case#of#drug#discovery#in#diabetes.##It#would#make#sense#to#use#
islets# in# their#native#3D#architecture,#however#2D#betaIcell#monolayers#are# still# in#
use#today.#
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diffusion# of# oxygen#within# islets# leads# to# hypoxic# or# necrotic# cores# that# result# in#
diminished#in#vitro#survival#and#function#[80I82].##Adding#to#the#issue,#islets#exist#in#
a#variety#of# sizes,# ranging# from#50# to#over#400#μm# in#diameter.# #Glucose#has#been#
shown#to#diffuse#with#little#effort#into#small#islets#(diameter#<#125#μm),#however#can#
only#penetrate# the#outer#most#cell# layers#of# large# islets# (diameter#>#150#μm)# [82].##
These#studies#go#on#to#reveal#several#functional#differences#between#small#and#large#
islets# [56,80I84].# # This# variability# in# size# (meaning# large# variations# in# cell#
numbers/islet),# and# variability# in# response# to# agonists# greatly# hampers# any#
attempts# to#use# intact# islets# for#drug#screening.# #For#now,# the#use#of#native,# intact#





an# analysis# of# the# current# status# impresses# upon# one# theme:# there# is# a# need# to#
develop# a# physiologically# relevant# alternative# for# diabetes# drug# testing.# # When#
developing# these# technologies# there# are# several# points# to# consider# for# obtaining#
more#clinically#relevant#results#(Table#2.2).##Novel#cellIbased#assay#technologies#for#
diabetes# drug# discovery# and# HTS# must# be# easily# translatable# to# the# commercial#
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sector#while#maintaining#ease#of#use#and#minimizing#additional#capital#expenditure.##









The# entire# process# from#drug#discovery# through#bringing# a# single# drug# to#market#
can#take#10#to#15#years.# #Patents#are#generally# filed#after#a#quality# lead#compound#
has#been#identified#to#protect#the#intellectual#property#and#provide#exclusivity#for#a#
20Iyear# period# from# the# date# of# application.# # An# investigational# new# drug# (IND)#
application# is# filed# with# the# FDA# during# preclinical# trials# to# allow# researchers# to#
transfer#the#drug#across#state#lines#for#further#development.##Once#an#IND#is#granted,#




































Using# twoIdimensional# betaIcell# monolayer# cultures# in# highIthroughput#
screening#is# insufficient#for#discovering#new#diabetes#drugs.# #Lacking#physiological#
relevance,#betaIcells#monolayers# lack# the#complexities#of#native# islets,#and#are#not#
sufficient# for# accurate# prediction# of# lead# compounds# during# pharmaceutical# drug#
discovery.# # Inherent# sizeIdependent# limitations#within# native# islets# can# alter# data#
and#lead#to#erroneous#conclusions.##The#superior#viability#and#functionality#of#small#
islets# (diameter# <# 125# μm)# in# comparison# to# large# islets# (diameter# ># 150# μm)#
demands# a# look# at# engineering# an# appropriate# solution.# # To# engineer# islets#while#
limiting# size# (below# 125# μm)# we# designed# a# glass# micromold# containing# conicalI
shaped# microIwells.# # Within# these# wells,# dispersed# islet# cells# spontaneously#
reaggregate# into# isletIlike# spheroids#within# the# geometric# constraints# of# the#well.##
The# glass# micromolds# can# be# reproducibly# fabricated# in# a# variety# of# shapes# and#
sizes.# # The# high# efficiency# production# of# engineered# islet,# or# Kanslets,# remained#
within# our# size# limitations.# # Using# the#micromold# lead# to# high# commercial# yields,#
producing# on# average# 20# Kanslets# per# mm2.# # In# highIthroughput# settings,# native#
islets# posed# problems# for# standard# equipment,# however# Kanslets#were# dispensed#
with# high# wellItoIwell# efficiency.# # Having# a# technology# to# produce# isletIlike#










Diabetes# affects# 8.3%#of# the#populations#within# the#United# States# and#over#
346#million#individuals#worldwide#[52,85].##The#economic#burden#within#the#United#
States#alone#exceeds#$200#billion#and#demands#the#need#to#do#research#and#develop#
new# and# successful# therapies.# # As# the# pharmaceutical# industry# continues# to# focus#
efforts# on# diabetes# drug# discovery,# the# currently# available# technologies# are#
insufficient# and# tools# for# discovering# the# next# generation# of# drugs# is# limited.# # A#
potential# contributor# to# this# issue# is# the# extensive# use# of# 2D# betaIcell# monolayer#
culture#as#the#primary#tool#for#modern#drug#discovery.#
The# complex# threeIdimensional# (3D)# cellular# environment# is# essential# in#
supporting#the#structure#and#function#of#cells#within#our#bodies.##This#environment#




vivo# environment.# # The# development# of# 3D# cell# culture# allows# for# physiological#
significance#when#providing#tools#for#drug#discovery#and#regenerative#medicine.##As#
researchers# transition# to# 3D# cell# culture,# we# begin# to# bring# relevance# between#
traditional#cell#culture#techniques#and#living#systems.#
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Whether# in# a# cellIbased# assay# for# primary# screening# in# a# highIthroughput#
screen# (HTS)# or# bench# top# in# vitro# experiments,# using#betaIcell#monolayers# limits#
the#possibility#to#accurately#and#predictably#discover#new#medicinal#entities#(NMEs)#




[39].# # Islets# are# much# more# complex# microIorgans# composed# of# a# variety# of# cell#
types# including# alphaI,# betaI,# and# deltaIcells# (glucagonI,# insulinI,# somatostatinI
secreting# cells;# respectively).# # These# small,# multiIcellular# clusters,# scattered#
throughout#the#pancreas,#play#a#vital#role#in#blood#glucose#level#maintenance.# #The#
paracrine# signaling# between# the# various# islet# cell# types# further# supports# the#
structureIfunction#relationships#that#is#essential#to#natural#islet#function#[68,72,86].##
Thus,#when# finding# drugs# that# treat# diabetes,# using# betaIcell#monolayers# for# drug#
screening#lacks#relevance#in#a#drug’s#action#on#a#more#complex#system.#
Unfortunately,# isolated# islets#provide# their#own#challenges.# # # Isolating# islets#
from# their# native# location# in# the# pancreas# has# a# profound# effect# on# oxygen# and#
nutrient#delivery,#ultimately#leading#to#core#cell#death#and#decreased#function.##With#
the# absence# of# the# native# blood# supply,# diffusion# becomes# the# primary#means# of#
transport#of#small#molecules#into#an#islet#[82,87].# #Islets#can#exhibit#core#cell#death#
within#24#hours#of#isolation,#leading#to#reduced#function#and#eventual#islet#loss#[80].##
The# size# of# islets# has# been#demonstrated# as# a# contributing# factor# toward# survival#
and# function.# # More# specifically,# small# islets# (diameter# <# 125# μm)# show# superior#
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functional#performance#and#increased#insulin#production#as#compared#to#large#islets#
(diameter#>#150#μm)# [56,80I84].# #Mathematical#modeling#supports# this# finding#by#
demonstrating# the# limited# diffusion# of# oxygen# into# the# core# of# islets# having# a#
diameter#larger#than#~100#um#[82].##When#perifused#with#fluorescent#glucose,#sizeI
dependent#penetration#of#the#islet#core#was#witnessed#[82].#
In# order# to# provide# a#more# suitable# alternative,# the# engineering# of# optimal#
isletIlike# clusters# could# overcome# the# diffusion# barriers# affected# by# islet# size#
limitations.# #Although#dispersing#islets# into#single#cells#would#greatly#decrease#any#
diffusion# barriers,# as#mentioned# previously,# dispersed# islet# cell#monolayers# show#
decreased# function.# # The# intracellular# interactions# are# vital# to# islet# phenotypic#
maintenance# [67,69,72I76].# # For# several# decades,# researchers# have#witnessed# the#
spontaneous#reaggregation#of#dispersed#islet#cells#and#have#attempted#to#utilize#this#
natural#phenomenon#in#reconstructing#isletIlike#tissues#[88I93].##In#the#early#forms#
of# “pseudoIislet”# formation,# islet# cells# were# incubated# in# culture# and# allowed# to#
reaggregate#into#structures#of#varying#shapes#and#sizes.##Often#times,#this#technique#
resulted# in# islets# larger# than# 200# μm.# # The# problem#with# this#methodology# is# the#
regeneration# of# large# cell# clusters—reintroducing# the# diffusion# barrier,# inferior#
viability,# and# reduced# function.# # Understanding# the# sizeIdependent# limitations#
within# islets,# engineering# islets# of# a# small# size# (less# than# 125#μm)# is# necessary# to#
prevent#restoration#of#these#inherent#issues.#
Researchers#are#developing#new#techniques#and#technologies#for#engineering#
islets# of# a# defined# size,# however# many# fail# to# catch# on# due# to# complications# or#










These# techniques#surely# improve#upon# the#original# formulated#method,#are#
automated,#and#claim#their#suitability#in#a#HTS#setting,#but#they#still#lack#scalability#
and# present# new# challenges.# # Current# technologies# for# HTS# aim# for# ultraIhigh#
throughput#(1536Iwells#or#more#per#plate)#and#are#using#smaller#solutions#such#as#
microarrays#[17,25,42,102,103].##The#development#of#384Iwell#hanging#drop#plates#
allows# HTS# automation# capabilities,# but# when# moving# forward# into# ultraIhigh#
throughput,# scalability# becomes# an# issue.# # Culture# medium# changes# within# these#
plates# require# careful# removal# and# dispensing# of# media# in# very# small# volumes#
within#each#individual#hanging#drop.##Furthermore,#a#humidifying#waterIreservoir#is#
required#to#prevent#evaporation#of#hanging#droplets#and#valuable#tissue#loss.##These#




be# produced# at# a# high# output# can# have# considerable# impact# on# diabetes# drug#
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discovery#and#3D#cell#culture.# #Next#generation#3D#cell#culture#technologies#should#
be# readily# accessible# and# easy# to# incorporate# into# the# already# expensive# HTS#
infrastructure.##Additionally,#they#should#be#easy#to#tailor#for#future#technologies#as#
industry# standards# change.# # Developing# a# high# quality# solution# should# reduce# the#
cost# of# employing# 3D# cell# culture# in# various# processes# and# increase# industry#
adoption.##
In# this# study,# we# have# developed# a# technology# to# produce# geometrically#
optimized# isletIlike# spheroids#with# increased# scalability# through# high# commercial#
yield# and# compatibility# with# drug# screening# highIthroughput# equipment.# # The#
primary# focus# in# developing# this# technology# was# limiting# the# diameter# of# islets#
during# reaggregation# to#no#bigger# than# a# small# islet# (diameter# less# than#125#μm).##
These# engineered# islets# were# produced# in# vitro# through# the# reaggregation# of#




effectively# engineering# isletIlike# clusters# with# geometric# constraints# (based# on#
previous# sizeIdependent# behavior)# and# provided# a# surface# for# highIoutput#
production#and#cell#culture#of#3D#tissue#spheroids.##Kanslets#can#easily#be#removed#
from# the# micromold# and# used# for# diabetes# drug# testing# and# other# in# vitro#






Rat# pancreatic# islets# were# isolated# and# dispersed# using# our# previously#
published# procedures# [80,82,104,105].# # Briefly,# rats# were# anesthetized# by#
intraperitoneal# injection# of# a# mixture# of# ketamine# (80# mg/kg;# Ketaject,# Phoenix#
Pharmaceuticals,# St.# Joseph,# MO)# and# xylazine# (10# mg/kg;# AnaSed,# Lloyd#
Laboratories,# Shenandoah,# IA).# #After# the#peritoneal# cavity#was# exposed,# the#main#
pancreatic#duct#to#the#duodenum#was#clamped,#cannulated# in#situ#via#the#common#
bile# duct,# and# distended# with# cold# collagenase# type# 1# (CLS1;# Worthington,#
Lakewood,#NJ).# #After#excision,#the#pancreas#was#incubated#for#20I30#minutes#with#
gentile#tumbling#in#a#37°C#incubator.##The#contents#of#the#tube#were#washed,#passed#
through#a#100#µm#mesh#screen,# and#sedimented# in#a# refrigerated#centrifuge.# #The#
pellet#was#mixed#with#Histopaque# (density# =# 1.1085)# and# centrifuged.# # The# islets#
collected#from#the#gradient#were#sedimented#and#washed#over#a#sterile#40#µm#mesh#











DiscIshaped,# sodaIlime# glass# substrate,# were# ordered# from# Precision# Glass#
and#Optics#(Santa#Ana,#CA).##The#glass#substrates#were#cleaned#for#20#minutes#each#
in#an#acid#piranha#solution#(70:30#H2SO4/H2O2)#followed#by#a#base#piranha#solution#
(70:30# NH4OH/H2O2)# to# remove# any# contaminants.# # Glass# substrates# were#
subsequently#dried#at#200°C#for#30I60#minutes#to#ensure#that#the#surface#was#free#
of#moisture.#
Glass# micromolds# were# fabricated# through# a# multistep# process# that# used#
thinIfilm# deposition,# photolithography,# and# wet# etching# techniques# (Figure# 3.1).##
Clean#glass#substrates#were#placed#in#a#Lesker#Thin#Film#Deposition#System.##A#300#
nm# layer# of# chromium#was# sputtered# onto# one# side# of# the# disc.# # Next,# a# positive#
photoresist#(AZ1518)#was#spinIcoated#onto#the#chromiumIcoated#surface#to#yield#a#




coated# substrate# was# exposed# to# UV# light# through# the# photomask# for# 4# seconds.##
Exposed#glass#was#postbaked#at#100°C#for#10#minutes#and#then#immersed#in#AZ#300#
MIF# Developer# to# render# the# image.# # The# chromium# layer# was# etched# with# the#
pattern# by# immersion# in# CR7S# Chromium#Etchant.# # Glass#was#washed#with#water#
and#dried#with#nitrogen#gas.#
To#etch#the#pattern#into#the#surface#of#the#glass,#the#disc#was#wet#etched#by#
immersion# in# a# buffered# oxide# etch# (BOE)# solution# containing# 14:20:66#
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HNO3/HF/H2O.# # Immersion# time# varied# from# 10I20# minutes# depending# on# the#
intended#etch#rate#and#the#freshness#of#the#BOE#solution.# #Due#to#isotropic#etching#
the#recess#depth#and#diameter#were#optimized#through#a#combination#of# template#
design,# immersion#time,#and#etch#rate.# #After# immersion# in# the#BOE#solution,#glass#
was# washed# with# a# calcium# carbonate# slurry# to# neutralize# HF# reactivity.# # A#
profilometer#(Tencor#Alphastep#200)#was#used#periodically# to#measure#the#etched#
surface# and# adjustments# in# immersion# time# were# made# accordingly.# # The#
photoresist#and#chromium#layers#were#then#removed#using#acetone#and#chromium#
etchant#respectively.##Glass#was#washed#with#water#and#dried#with#nitrogen#gas.#
To# contain# the# cell# culture# on# top# of# the# glass# micromold,# a# large#
polydimethylsiloxane# (PDMS;# Sylgard# 184;# base# and# crossIlinker;# Dow# Corning,#
Midland,#MI)#well#was#molded#to#surround#the#glass#disc.##PDMS#is#a#siliconeIbased#
polymer# that# is# translucent,# sterilizable,# and# often# used# in# experiments# in# direct#
contact#with#cells#[106].##The#base#and#curing#agent#were#mixed#at#10:1#ratio#(base#
to#curing#agent)#and#deposited#into#a#copper#mold.##The#PDMS#was#cured#in#an#oven#









free# HBSS# (cmfIHBSS)# before# addition# of# digestion# medium# containing# cmfIHBSS#
supplemented#with#4.8#mM#HEPES#and#papain#(5#units/ml;#Worthington,#Lakewood,#
NJ).# # Tubes# were# incubated# on# a# rotator# at# 37°C# for# 20# minutes.# # Islets# were#
dispersed#by#trituration#using#a#pipette#until#the#cell#suspension#primarily#contained#
single#cells.##The#papain#reaction#was#stopped#by#adding#complete#media#containing#
calcium,# magnesium,# and# FBS.# # The# cells# were# then# washed# to# remove# residual#
papain# and# transferred# to# a# Kanslet# aggregate# culture# medium.# # The# Kanslet#
aggregate#medium#consisted#of#DIMEM:F12#or#CMRL1066#supplemented#with#10%#





and# maintained# to# minimize# diffusion# issues# due# to# culture# medium# height.#
Micromolds#were# incubated# for# 5I7# days# at# 37°C# and# 5%#CO2.# # Aggregate# culture#
medium# was# changed# every# 24I48# hours# until# reaggregated# islets# were# formed.##
Kanslets# were# removed# by# washing# the# micromold# several# times# with# culture#




# A# known# concentration# of# islets# and# Kanslets# were# suspended# in# culture#









camera# or# an# Olympus# confocal# microscope# housed# at# the# Diabetes# Research#
Laboratory# at# the# University# of# Kansas#Medical# Center.# # Images#were# acquired# at#
10XI100X# an# analyzed# using# Olympus# FluoView,# Adobe# Photoshop,# or# Lumenera#
Infinity#Analyze.#
Islet# volumes# were# calculated# by# measuring# the# islet# diameter# and# then#
converting# it# into# islet# equivalents# (IEQ)# or# cell# number# [105].# # A# hemocytometer#
was# used# to# estimate# cell# number# when# islets# were# dispersed# in# a# single# cell#
suspension.# # Yield# was# calculated# by# comparing# IEQ# or# cell# number# before# islet#
dispersion# and# after# Kanslet# production.# # Islet# diameter# was# measured# using# an#
ocular# micrometer,# FluoView# Software,# or# Infinity# Analyze.# # We# measured# the#
diameters#of#Kanslet#samples#produced#over#various#preparations#to#determine#the#
production# uniformity# between# preparations.# # Several# samples# were# taken# from#








Overall,# the#micromolds#were# simple# to# use# for# tissue# spheroid#production#
(Figure#3.2).##After#islet#cells#had#been#dispersed#into#single#cells,#the#cell#suspension#
was# loaded# directly# on# top# of# a#micromold,# and# after# several# days# Kanslets#were#
produced.# #Within#24#hours#of# seeding,# cells#had# settled# into#wells# and#very# loose#
aggregates# had# started# to# form.# # Over# the# next# several# days,# loose# aggregates#
coalesced# into# a# tighter# conformation# and# developed# an# isletIlike# morphology#
(Figure#3.3).# #Removing#Kanslets# from# the#micromold# is# as# simple# as#washing# the#








media# in# individual#wells#by#simply#covering# the#entire#micromold#well# surface# in#
culture#media.##To#keep#with#this#requirement,#a#PDMS#wall#was#molded#to#surround#
the# disc,# creating# a# selfIcontained#micromold# (Figure# 3.4C).# # In# the# selfIcontained#
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version,# changing# culture#media# took# replacing#50%#of# the#media# in#a# single# step.##
Culture# medium# was# changed# at# a# slow# rate# to# prevent# unIaggregated# cells# or#
spheroids#from#shifting.#
The#micromold#itself#contains#conicalIshaped#microIwells#were#200I240#μm#
in# diameter# and# 70# μm# deep.# # The# design# process# underwent# several# iterations#
before# resulting# in# success.# # A# modified#multiIlayer# approach# using# a# chromiumI
layer# and#photomask,# allowed# increased#well# depth# (70#μm)# compared# to#using# a#
photomask#alone# (<#5#μm)# [107,108].# # In#addition# to#a#deep#etching#strategy,#well#
placement#became#crucial# (Figure#3.5).# # In#an#early#design,#wells#contained#spaces#




fluid# flow# shifted# some# of# these# cells# into# wells,# additional# single# cells# remained#
separately#on#the#surface.#
In# the# current# design,# wells# are# placed# in# close# proximity,# increasing# the#
probability#cells#would#fall# into#wells#(Figure#3.5B).# #We#were#able#to#decrease#the#
space#between#wells#to#less#than#20#μm,#ensuring#that#wells#did#not#merge#together.##
Using# these#micromolds,# all# loaded# cells# settled# into# the#wells# leaving# little# or# no#
cells# in#the#remaining#space.# #This#micromold#version#contained#over#15,000#wells#
on# a# 33#mm#diameter# disc.# #When#well# sizes#were# on# the# smaller# end# (~195# μm#
diameter),#micromolds#contained#up#to#23,000#wells#in#the#same#area.#
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To# determine# the# production# efficiencies#we# calculated# a# commercial# yield#
based#on#the#number#of#Kanslets#that#were#produced#on#a#single#micromold#during#
a# preparation.# # We# averaged# a# commercial# yield# of# 16483# ±# 6384# Kanslets# per#
micromold.# #This# is# significant#because#we#are#able# to#produce#more#Kanslets#per#
area# compared# to# other# methods# (Figure# 3.6).# # Compared# to# a# 384Iwell# hanging#
drop#plate#(producing#only#a#single#spheroid#per#well;# less#than#1#spheroid/mm2),#
we#exceed#the#production#capacity#by#43#times#(19#Kanslets/mm2).#The#micromold#
in# our# examples# are# only# 33Imm# in# diameter,# although# glass# micromolds# can# be#
fabricated# in# a# variety# of# shapes# and# sizes.# # If#micromolds#were#built# to# the# same#
area# specification# as# standard# 384Iwell# hanging# drop# plates# or# potentially#
developed#1536Iwell#hanging#drop#plates,#we#could#increase#production#to#200,000#
spheroids#(520#times#more,#130#times#more;#respectively).#
Since# our# goal# was# to# produce# spheroids# that# were# below# 125# μm# in#
diameter,#we#defined#uniformity#as#the#production#of#spheroids#in#a#range#between#
25# and# 125# μm.# # On# occasion,# we# found# that# some# wells# contained# multiple#
aggregates#instead#of#a#single#Kanslet.# #Since#these#aggregates#were#still#within#the#
size# limit,# they#were#considered#as#Kanslets.# # In#general,#we#were#able# to#produce#
Kanslets#with#an#average#diameter#of#49#±#25#μm#with#99.2%#having#a#diameter#less#
than# 125# μm# (n# =# 3501# Kanslets).# # The# size# uniformity# between# various# Kanslet#
preparations# remained# consistent#with# diameters# averaging# 49# ±# 2# μm# (standard#
error)# (Figure#3.7).# # The#production#uniformity# remains# evident# in# comparison# to#
native#islets,#which#have#a#size#range#of#50#μm#to#over#300#μm#(Figure#3.8).#
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Using# Kanslets# can# provide# a# lot# of# benefits# for# commercial# use# in# a# highI
throughput# setting# in# comparison# with# attempts# to# use# native# islets.# # In# our#
experimental# commercial# run,#we#attempted# to#dispense#native# islets# (2#per#well)#
and# Kanslets# (20# per# well)# into# 384Iwell# plates# using# automated# dispensing#
instruments# common# in# commercial# drug# screening.# # These# dispensing# numbers#




When#working#with# intact#native# islets,# the# instrument#dispensed#2.5#±#1.8#
islets#per#well#(range:#0#to#9#islets#per#well).# #Unfortunately,#over#10%#of#the#wells#
were# empty,# dispensing# media# without# an# islet# (Figure# 3.9).# # To# generate# plates#










developed# to# produce# 3D# cell# clusters.# # Unfortunately,# cost,# ease# of# use,# and#
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scalability# are# among# the# problems# that# hinder# commercial# acceptance# of# such#
products.# # In#developing#our#micromolds,#we#have#provided#a# technology# that#can#
easily#be#translated#for#commercial#applications.#
The# use# of# betaIcell# monolayers# as# an# in# vitro# representation# for# natural#
islets#is#insufficient#[39].##Introducing#isolated,#native#islets#as#a#solution#may#seem#
viable.# # However,# it# too# comes# with# inherent# issues# [56,80,82I84].# # Given# these#
known# issues,# engineering# optimal# isletIlike# spheroids# can# produce# an# applicable#
solution# for# use# as# an# alternative# to# betaIcell# monolayers.# # When# designing# our#
technology,# in# addition# to# the# geometric# considerations,# were# several# key# factors#
enabling#commercial#use.##These#included#(1)#simple#production#of#3D#spheroids,#(2)#
high# commercial# yields,# (3)# use# with# current# standard# equipment# for# highI
throughput#screening,#and#(4)#scalability#for#today#and#tomorrow.#
Through# a# combination# of# micromold# design# and# a# multiIstep# fabrication#
process,#we#produced#micromolds#containing#microIwells#of#a#defined#geometry#for#
optimally# engineering# islets.# # Engineering# islets#was#made# to# be# a# simple# process#
including#simple#cell#seeding#onto#micromolds,#subsequent#cell#culture#with#culture#
media# changes,# and# easy# removal# of# produced# spheroids.# # Additionally,# by# using#
glass,# micromolds# were# cheap,# sterilizable,# reusable,# transparent,# and# compatible#
with#in#vitro#cell#culture.#
The# micromold# was# specifically# designed# for# simpler# use# compared# to#
currently#available#products.##All#of#the#wells#within#the#micromold#were#placed#on#a#
single# surface# allowing# simple# loading# of# a# cell# suspension.# # This# allowed# cells# to#
settle#into#wells#and#made#culture#medium#changes#simple.##Some#technologies#are#
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faced#with# the# inability# to#easily# remove#or# retrieve#spheroids#after# formation.# # In#
our# case,# we# were# able# to# simply# wash# the# micromold,# collecting# over# 10,000#
spheroids#from#a#single#preparation.#
Kanslets# demonstrated# a# higher# dispensing# efficiency# when# utilizing#
automated# dispensing# systems# to# load# highIthroughput# plates.# # Because# Kanslets#
can#be#easily#removed#from#the#molds,#they#can#be#loaded#using#industry#standard#
technology# into#commercially#available#plates.# # In#a#384Iwell#plate,#we#are#able# to#
maintain# dispensing# efficiency# using# Kanslets.# # Dispensing# native# islets# remains#
inaccurate# with# wellItoIwell# volume# differences# being# large.# # This# variability# in#
volume# remains# large# even# if# a# single# islet# per# well# was# dispensed.# # Dispensing#
Kanslets#was#more#efficient# in#decreasing# the#wellItoIwell# accuracy.# #Although#we#
loaded#20#Kanslets#per#well,#it#should#be#possible#to#gain#similar#results#at#a#smaller#
number#per#well.# #Simply#put,#since#native#islets#have#a#broad#size#range,#large#and#
small# islets#will# have# different# properties#when# flowing# through# liquid,# and# often#
times# cannot#be#uniformly#held# in# suspension# for# even#dispensing.# # This# islet# size#









and# dispensing# volume# used# in# many# of# these# large# systems# are# designed# to#
accommodate#a#variety#of#well#plates.# #When#moving# to#smaller#well#sizes#such#as#
1536Iwell# plates# and# those# being# designed# for# ultrahighIthroughput# screening,#
nozzles# get# smaller,# liquid# volumes# are# smaller,# and# dispensing# larger# object#
becomes#more#difficult.#
Ultimately,#we#satisfied#our#primary#goal#by#successfully#producing#isletIlike#




to# transition# away# from# 2D# betaIcell# monolayers.# # Though# we# successfully# have#
produced# an# isletIlike# structure,# our# next# step# will# be# to# characterize# them# in#
comparison#to#native# islets# in# terms#of# functionality.# #As#a#whole,#Kanslets#contain#
the#multiple# cells# types# that#make# up# native# islets# from#which# hey# are# produced.##
This# means# that# when# the# cells# are# reaggregated,# the# new# organotypic# structure#
should# mimic# islet# structure# and# function.# # In# providing# a# comparison# to# native#
islets,# we# will# need# to# examine# if# we# have# overcome# the# inherent# issues# within#
native# islets.# # This# characterization# should# examine# cell# composition,# viability,#
glucose#diffusion,#and#glucoseIdependent#insulin#section.#
This# study# was# a# basic# proofIofIconcept# demonstration# of# the# micromold#




living# systems,#bridging# the#gap#between# in# vitro# experimentation,# animal# studies,#
and# eventual# human# application.# # The# significance# of# this# technology# can# impact#










The#micromold# fabrication# process# for# deep#well# etching# consists# of# a#multilayer#
approach#consisting#of#chromium#and#photoresist.##This#multistep#process#requires#










To# produce# Kanslets,# a# pancreas# is# harvested# from# the# donor# (A)# and# islets# are#
enzymatically# isolated# from# the# exocrine# tissue# (B).# # Islets,# composed# of# various#
sizes,# are# dispersed# into# single# cells# and# seeded# onto# the#micromold# (C).# #Within#



































































































drug#discovery# in# order# to# develop# therapies# for# diabetes.# # Empirical#modeling# of#
islet# diffusion# barriers# demonstrated# that# only# the# outermost# layers# of# cells#were#
exposed#to#glucose#and#sufficient#oxygen# levels,# resulting# in#core#cell#death.# # Islets#
under#a#diameter#of#100#μm#exhibited#a# lower#diffusion#barrier,# superior# survival#
rates,# and# improved# functional# properties.# # Utilizing# these# observations# we#
engineered# optimal# islets# by# dispersing# them# into# single# cells# and# reaggregating#
them# over# several# days# in# a# micromold.# # These# customIdesigned# micromolds#
contained# conicalIshaped# recesses# that# enhanced# reaggregation# of# cells# into# a#
defined# geometry.# # The# engineered# islets,# or# Kanslets,# were# all# under# 100#mm# in#
diameter,#and#had#the#same#general#cellular#composition#as#native# islets.# #Kanslets#
continued#to#produce#new#insulin#molecules#and#had#microvilli#on#the#islet#surface,#
much# like# native# islets.# # The# engineered# islets# had# a# statistically# higher# viability#
(percent#of#live#cells),#and#increased#glucose#diffusion#compared#to#native#islets.##In#
addition,# they# remained# responsive# to# varying# glucose# levels# by# secreting# insulin.##
When# transplanted# into# diabetic# rats,# engineered# islets# performed# identical# to#
native#islets#in#reducing#blood#glucose#to#normal#levels.##Optimally#engineering#islets#
########################################################






applications.# # Reaggregating# tissue# in# an# optimized#manner# using# our# engineered#




There#are#over#18.8#million# individuals# in# the#United#States#diagnosed#with#
diabetes#due#to#disregulation#of#blood#glucose#levels#[52].##Islets#of#Langerhans#are#
cell#clusters#within#the#pancreas#composed#of#a#variety#of#cell#types#including#alphaI,#
betaI,# and# deltaIcells,# and# are# responsible# for# the# maintenance# of# blood# glucose#
level.# # Lymphocyte# destruction# of# betaIcells# (insulinIproducing# cells)# or# failure# to#
utilize# insulin# are# the# hallmark# events# that# result# in# type# 1# and# type# 2# diabetes,#
respectively.# # Monitoring# blood# glucose# levels# and# administration# of# insulin#
injections# remain# the# primary# therapies# currently# available# to# patients,# requiring#
stringent# patient# compliance.# # Individuals# suffer# from# chronic# complications#
including#kidney#failure,#blindness,#amputations,#and#even#death.##There#is#an#urgent#
need# to# provide# better# solutions# as#we#move# forward# in# treating# this# debilitating#
disease.#
Isolating# islets# from# the# pancreas# of# cadaveric# donors# provides# tissue# that#
can#be#used# for#both# transplantation# and#drug#discovery.# # Significant# strides#have#
been#made# to# offer# pancreatic# islet# transplantation# as# a#means# to# achieve# insulin#
independence# [109I113].# # With# the# advent# of# the# Edmonton# protocol,# recipients#
were# able# to# maintain# normoglycemia# for# a# full# year# after# islet# transplantation#
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[114].# #Unfortunately,# regardless#of# these# results,# longIterm#success# is# limited#and#
patients# are# subject# to# receiving# multiple# transplants# to# maintain# insulin#
independence# [115,116].# #With# each# transplant# requiring# islets# from# two# to# three#
donor#pancreata#and#patients#needing#subsequent#transplantations,#a#large#burden#
is#placed#on# the#already# limited#donor#availability,#preventing# the#procedure# from#
being#accepted#as#a#clinical#standard#and#reaching#the#greater#population.###
# Once# isolated# from# their#natural# location#within# the#pancreas,# islets#exhibit#
diminished# survival# and# function,# both# in# vitro# studies# and# soon# after#
transplantation# [80,82I84].# # Within# the# pancreas,# islets# are# immersed# with# their#
native# blood# supply.# # After# isolation,# diffusion# becomes# the# primary# means# of#
oxygen,# glucose,# and#nutrient# transport# into# the# core#of# isolated#native# islets# [82].##
Revascularization# is# essential# for# islet# survival# and# function# after# transplantation,#
but# this# process# can# take# several# days# or# even# weeks# to# occur# [87,117,118].##
Diffusion#barriers,#particularly#with#respect#to#oxygen,#affect#the#maintenance#of#cell#
viability#and#performance.##The#limited#diffusion#of#oxygen#into#the#core#of#a#native#
islet# can# lead# to# reduced# function,# core#cell#death,# and#eventual# islet# loss.# # Studies#
have# reported# that# the# size# of# an# islet# has# a# profound# effect# on# its# survival# and#
function#[80I82,84].##Several#studies#have#demonstrated#that#small#islets#(diameter#
<# 125# µm)# were# superior# large# islets# (diameter# ># 150# µm)# in# vitro,# and# showed#









Engineering# optimal# islets# provides# a# means# to# overcome# the# diffusion#
barriers#affected#by#islet#size#limitations.##Although#dispersing#islets#into#single#cells#
would# greatly# decrease# any# diffusion# barriers,# it# is# well# known# that# islet# cells#
function#better#when#clustered#and#are#highly#dependent#on#cellIcell#communication#
and# the# paracrine# interactions# between# the# different# cell# types# [67I
71,73,74,76,86,119,120].# # For# several# decades,# researchers# have# witnessed# the#
spontaneous# reaggregation# of# dispersed# islet# cells# and# have# utilized# this# in#
reconstructing# isletIlike# tissues# [88I93].# # Traditionally,# islet# cells# have# been#
incubated# in# culture# medium# and# allowed# to# reaggregate# into# pseudoIislets# of# a#
variety#of#shapes#and#sizes,#often#times#resulting#in#pseudoIislets#much#larger#than#
200#µm#in#diameter.##The#problem#with#this#methodology#is#the#high#probability#of#
regeneration# of# large# cell# clusters—reintroducing# the# diffusion# barrier,# inferior#











reaggregation# of# islet# cell# clusters# can# have# a# considerable# impact# on# islet#
production#for#research#and#transplantation.#
# In# this# study,#we# focused# on# limiting# the# diameter# during# reaggregation# of#
islet#cells#to#that#of#small# islets#(less#than#125#µm).# #We#engineer#optimal#islets,#or#
Kanslets,# in# vitro# by# reaggregating#dispersed# islet# cells#on#a#glass#mold# containing#
microIrecesses#of#a#defined#geometry.##Use#of#this#tool#resulted#in#the#production#of#
uniform,#reproducible#Kanslets.#We#assessed#several#characteristics#of#the#Kanslets#
and# compared# their# function# to# that# of# isolated# native# islets.# # Finally,# we#
transplanted#the#engineered#Kanslets#into#diabetic#rats#and#compared#the#response#
to#matched#animals#receiving#native#islets.# # In#summary,#we#have#developed#a#tool#








piranha# solutions# and# dried# at# 200°C# to# ensure# the# surface#was# free# of#moisture.##
Glass#micromolds#were# fabricated# through#a#multistep#process# that# included# thinI
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film#deposition,#photolithography,#and#wet#etching#techniques.##Briefly,#one#surface#
of# the#glass# substrates#was#sputtered#with#a# layer#of# chromium#(Lesker#Thin#Film#
Deposition# System).# # Positive# photoresist# (AZ1518)# was# spinIcast# onto# the#
chromium# surface# and# preIbaked# at# 100°C# for# 2# minutes.# # A# transparency# mask#
template# was# created# containing# the# defined# geometry# and# layout# of# wells# to# be#
etched#using#computerIassisted#design#(CAD)#in#AutoCAD#software#(Autodesk)#and#
highIresolution# transparency# masks# were# printed.# # The# photoresistIcoated# discs#
were#exposed#to#UVIlight#through#the#transparency#mask#for#4#seconds.##Patterned#
glass#was#then#postIbaked#at#100°C#for#10#minutes#and#then#immersed#in#developer#




immersion# in# a# buffered# oxide# etch# (BOE)# solution# containing# a# 14:20:66# ratio# of#
HNO3# to#HF# to#H20# respectively.#A#profilometer# (Tencor#Alphastep#200)#was#used#
periodically#to#measure#the#etched#surface#and#adjustments#were#made#accordingly.##
The# photoresist# and# chromium# layers# were# removed# to# reveal# the# etched#
micromold.##
# To# contain# the# cell# culture# on# top# of# the# glass# micromold,# a#
polydimethylsiloxane#(PDMS;#base#and#crossIlinker;#Dow#Corning,#Midland,#MI)#ring#








pancreatic# main# duct# to# the# duodenum# was# clamped,# cannulated# in# situ# via# the#
common# bile# duct,# and# distended# with# cold# collagenase# (CLS1,# 450# units/ml;#
Worthington,#Lakewood,#NJ).# #After#excision,#the#pancreas#was#incubated#for#20I30#
minutes#with#gentle# tumbling# in#a#37°C# incubator.# #The#contents#of# the# tube#were#
washed,#passed# through#a#100#µm#mesh# screen,# and# sedimented# in# a# refrigerated#
centrifuge.# # The# pellet# was# mixed# with# Histopaque# (density# =# 1.1085)# and#
centrifuged.# #The# islets,# collected# from#the#gradient,#were#sedimented#and#washed#
over#a#sterile#40#µm#mesh#cell#strainer.##Islets#were#placed#into#a#modified#DMEM/FI
12# medium# supplemented# with# 10%# fetal# bovine# serum# (FBS),# 1%#
antibiotic/antimycotic#and#allowed#to#recover#overnight#in#an#incubator#at#37°C#and#
5%#CO2.#





until# the# cell# suspension# primarily# contained# single# cells.# # The# cells# were# then#
washed# to# remove# residual# papain# and# transferred# to# a# customized# DMEM:F12I
# 61#
based,# serumIfree#Kanslet# aggregate# culture#medium.# #Occasionally,# a# sample#was#
taken#and#cell#counts#and#yield#were#determined#using#a#hemocytometer.##
# The# single# cell# suspension# was# then# carefully# plated# onto# sterile# glass#
micromolds.# # #Within#several#minutes,#cells#began#to#settle# into#the#recesses#of#the#
micromold#and#were#in#close#proximity#to#each#other#allowing#cellIcell#reIadhesion.##
Micromolds#were# incubated# for#6I7#days#at#37°C#and#5%#CO2.# #Cells# reaggregated#
while# limiting# the# size# to# no# bigger# than# the# recess# allowed.# # Aggregate# culture#
medium#was#changed#every#24#to#48#hours#until# reaggregated# islets#were# formed.##




Viability# of# Kanslets# was# assayed# by# placing# them# in# PBS# in# an# Attofluor#
Chamber.# # Apoptotic# and# necrotic# fluorophores# (Propidium# Iodide# and#YOIPROI1;#

















graded# ethanol# dehydration# (30%,# 70%,# 80%,# 95%,# 100%)# for# 10# minutes# each.##
Samples# were# rinsed# twice# in# propylene# oxide# for# 15# minutes# prior# to# being#
infiltrated# in# a# mixture# of# propylene# oxide# and# Embed# 812# resin# (Electron#
Microscopy#Sciences,#Ft.#Washington,#PA)#overnight.# #BEEM#capsules#were#used#to#













decreased#after# several#minutes# for# the# remainder#of# the#experiment.# #The# rate#of#
glucose#was#measured#from#the#time#the#outer#cells#became#fluorescent#to#when#the#
core#cells#became#fluorescent.##The#percentage#of#2INBDG#uptake#was#calculated#by#




Kanslet# samples# were# fixed# in# 4%# paraformaldehyde# in# 0.1# M# phosphate#
buffered#saline#(PBS,#pH#7.4).# #Cellular#composition#of#Kanslets#was#determined#by#
tripleIstaining#islets#for#insulin,#glucagon,#and#somatostatin.##The#following#primary#
antibodies# were# used:# antiIinsulin# (Abcam# or# Santa# Cruz# Biotechnology),# antiI
glucagon# (Abcam)# and# antiIsomatostatin# (Abcam).# # Corresponding# secondary#
antibody# conjugates# included:# Cy2# (Jackson# ImmunoResearch# Laboratories# Inc.),#
Alexa#647,#and#Alexa#555#(Molecular#Probes,#Invitrogen).#
Images#were#obtained#using#a#Nikon#C1Si#or#a#C1Plus#confocal#microscope.##




the# confocal# image.# # Kanslet# cellular# composition# was# compared# to# native# islets.##





Kanslets#were# equilibrated# overnight# in# DMEM/FI12#medium# containing# 5#
mM#glucose#and#10%#FBS# (low#glucose#medium).# # Islets#were#handpicked#using#a#
micropipette#and#a#known#quantity#of#islet#equivalents#were#distributed#in#24Iwell#
plates.##Kanslets#were#subject#to#low#glucose#(5#mM),#high#glucose#(17.5#mM)#or#high#
glucose#with#KCl# (30#mM).# #After# 60#minutes# of# static# incubation# at# 37°C# and#5%#







then# subjected# to# 3# testing# conditions# during# a# 3Ihour# incubation# period:# # 60#
minutes# of# basal# condition# (3#mM# glucose),# then# 60#minutes# of# high# glucose# (20#
mM),# followed# by# 60# minutes# of# basal# condition# (3# mM# glucose).# # During# the#
perifusion,#samples#of#conditioned#medium#were#collected#from#the#output#fraction#






Islet# transplantation#was# completed# using# our# published# protocols# [80,82].##
Diabetes#was# induced# in# Sprague#Dawley# (SD)# rats# by# intraperitoneal# injection# of#
streptozotocin#(65#mg/kg#body#weight).##Rats#were#monitored#for#1#week#to#ensure#
that#they#were#diabetic,#with#blood#glucose#levels#above#250#mg/dl.# #Animals#were#




wall# on# the# left# flank.# # The# kidney# was# exposed# through# the# wound# and# a# small#
incision#made# into# the#kidney#capsule.# #Using#a#smallIbore#pipette,#native# islets#or#
Kanslets#were# placed# under# the# capsule.# # The# kidney#was# returned# to# its# original#
position,# the#muscle#was# sutured,# and# the# skin# closed#with#wound# clips.# #Novolog#
insulin# (0.55# units/kg)# injections# were# given# twice# daily# postItransplant# until#
transplants#provided#the#recipient#with#necessary# insulin,#which# in# the#case#of# the#











Visualization# of# the# reaggregated# Kanslets# indicates# that# they# were# below#
100#μm#in#diameter,#as#shown#in#Figure#4.1A.#These#islets#generally#measured#less#
than# 100# µm# with# an# average# diameter# of# 40.85# ±# 0.39# µm.# # In# contrast,#
reaggregated# islet# cells# that# were# not# constrained# by# the# micromolds# often#
reaggregated# in# an# unconstrained# manner# forming# megaIislets# measuring# more#
than#200#µm#in#diameter#(Figure#4.1B).# #A#size#histogram#of#Kanslets#compared#to#
native#rat#islets#is#provided#in#Figure#4.1C.#
It# is# important# that# the# Kanslets# return# to# native# islet# morphology# after#
formation,# including# the# appearance#of#microvilli# covering# the# surface#of# the# islet.#
Figure# 4.2A# and# B# compare# the# islet/Kanslet# general# morphology# illustrating# the#
similarity.#Electron#micrographs#highlight#the#microvilli# that#cover#the#surface#of#a#






was# performed# on# day# 5# (after# reaggregation# of# islet# cells).# # Very# few# Kanslets#
exhibited# any# dead# cells,# with# some# exhibiting# a# few# random# dead# cells.# # For# the#
most#part,#dead#cells#were#attached#to#the#surface#of#the#Kanslets,#and#visibly#were#







work# on#native# islets,#we# used# a# fluorescent# glucose# analog,# 2INBDG.# # Islets#were#
exposed# to# 0.5# mM# 2INBDG# though# perifusion# and# monitored# under# a# confocal#
microscope.##Glucose#diffused#into#the#intracellular#spaces#almost#as#immediately#as#
glucose#was# apparent# in# the# viewing# field.# # Figure# 4.4A# shows# the# lack# of# glucose#
diffusion#into#a#native#islet#compared#to#full#penetration#in#a#Kanslet#(Figure#4.4B).##
In# fact,# the#Kanslet#showed#superior#glucose#uptake#with#diffusion#rates# that#were#
beyond#our#ability#to#resolve#with#an#imaging#scan#speed#of#2#scans/sec.#As#soon#as#
the#glucoseIcontaining#media#came#in#contact#with#the#Kanslet,#it#entered#the#core.##




Immunofluorescence# staining#was# conducted# to# ensure# that# Kanslets# were#
similar# in#cellular#composition#to#their#native#counterpart.# #Kanslets,# tripleIstained#
for#insulin,#glucagon,#and#somatostatin,#indicate#that#the#three#major#endocrine#cell#
types#were#present#in#our#engineered#constructs#(Figure#4.5A).##The#distribution#of#
these# cell# types# across# the# islet# appears# to# be# in# a# random# order.# # In# general# the#
composition# was# not# radically# different# from# native# islets,# even# though# Kanslets#
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consisted# of# a# significantly# larger# portion# of# betaIcells# compared# to# native# islets#
(Figure#4.5B).#
The#production#of#new# insulin#molecules#was# identified#by# staining# for# the#
insulin#precursor#molecule,#proinsulin.##The#presence#of#proinsulin#in#islets#indicates#






concentrations# in# static# culture.# # Kanslets# responded# to# glucose# as# expected#with#
increased# insulin#secretion#as# the#glucose# level# increased# (Figure#4.7A).# # #Kanslets#
subjected#to#high#glucose#resulted#in#a#significant#increase#in#insulin#output,#double#




Perifusion# experiments# were# completed# to# test# the# insulin# secretion# over#
time# (dynamic# secretion)# in# response# to# varying# glucose# levels.# # Kanslets# were#
subjected#to#basal#glucose,#then#high#glucose,#and#again#basal#glucose#over#a#3Ihour#
period.##Insulin#secretion#remained#stable#in#response#to#basal#glucose,#and#resulted#
with# a# spike# in# insulin# secretion# immediately# upon# exposure# to# a# high# glucose#
concentration.##Insulin#secretion#more#than#doubled#in#response#to#the#presence#of#
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StreptozotocinIinduced#diabetic# rats# received# transplantation#of#1500I2000#
IE#of#either#native#islets#or#Kanslets#under#the#kidney#capsule.##PostItransplant#blood#
glucose#values#were#monitored#for#an#initial#2#weeks#following#transplant.# #In#both#
cases,#diabetes#was# reversed#within#days# in# rats# following# transplantation# (Figure#
4.8).# # In# fact,# insulin# injections# were# halted# in# the# rats# receiving# Kanslets# a# day#














oxygen# and# glucose,# allowing# for# increased# viability# and# longIterm# performance.##
Uniform,#engineered#islets#were#produced#by#dissociating#islets#into#single#cells#and#
utilizing#a#micromold#to#optimally#reaggregate#the#cells.##This#uniformity#of#size#was#
limited# to# a# maximum# diameter# of# 125# μm,# because# the# critical# oxygen#
concentrations# resulting# in# core# cell# death# above# this# diameter# as# previously#
described#[80,82].##By#limiting#the#diameter#of#this#engineered#islet#tissue,#we#were#
able# to# increase# the# viability# to# nearly# 100%;# a# significant# improvement# over#




in,# or# lack# of,# a# glucose# diffusion# barrier# as# Kanslets#were# nearly# instantaneously#
infiltrated#with#the#fluorescent#tag.##This#is#in#contrast#to#the#published#diffusion#rate#
of# 2.8# mm/min# into# native# large# islets,# indicating# an# extremely# slow# penetration#
[82].# #Previous#experiments#with#glucose#diffusion# into#native# islets# indicated# that#
even#after#1Ihour#of#incubation,#fluorescent#glucose#penetrated#only#the#outermost#
layers# of# a# large# islet#while# diffusing#with# an# increased# efficiency# into# small# islets#
[82].# #Our#results#replicated#previously#published#data,#while#using#a#much#smaller#
concentration#of#labeled#glucose#(0.5#mM#2INBDG)#[82].##Our#results#show#that#the#
diffusion# barrier# to# glucose# was# markedly# reduced# and# support# the# necessity# to#
produce#islets#less#than#100#μm#in#diameter.#
The# engineering# process# allowed# for# successful# production# of# islets# that#
contained# alphaI,# betaI,# and# deltaIcells,# and# was# similar# in# composition# to# their#
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native#islet#counterparts.##It#is#unknown#why#there#was#a#slight#increase#in#betaIcells#
in#Kanslets# and#may#be#due# to# the# engineering#process.# # It# is#possible# that#during#
islet# isolation# from# the# pancreas,# a# portion# of# the# outer# islet# cells,# which# are#
predominantly#alphaI#and#deltaIcells,#may#have#been#lost.##This#is#not#necessarily#a#
negative#outcome#as#this#restructured#composition#may#be#more#ideal#compared#to#
native# islets# for#both#research#and#transplantation.# #Allowing#the# islet#cells# to#selfI
aggregate# into# an# islet# may# allow# for# cellIcell# communication# and# signaling# that#
leads# to# an# increased# incorporation# of# betaIcells.# # Given# that# native# islets# contain#
blood# vessels,# there# is# a# great# probability# that# insulin# will# be# secreted# close# to# a#





Given# the# similarities# in# islet# composition,# it# is#not# surprising# that#Kanslets#
responded#to#changes#in#glucose#levels#as#expected.##Kanslets#secreted#more#insulin#
when# exposed# to# high# glucose# levels# over# the# basal# level.# # This# increase# could# be#
witnessed# in# static# and# dynamic# experimental# conditions,# with# insulin# levels#
returning#to#normal#after#high#glucose#stimulation#ceased#in#dynamic#experiments.##
Kanslets# were# able# to# provide# a# transplantable# solution# that# matches# the#
effect#of#native#islets.##As#expected,#there#was#a#reduction#in#blood#glucose#levels#in#
diabetic#rats#that#received#the#Kanslet#transplant.# #More#notably,#these#levels#were#
similar# to# those#produced#by# the#native# islet# transplant# group.# # In# this# study,# rats#
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were#transplanted#with#approximately#the#same#amount#of#islet#tissue.#Although#our#
findings# show# similar# results# between# treatments,# it# is# uncertain# at# this# time#
whether# Kanslet# transplants# are# more# potent# or# outperform# native# islets# with# a#
lower# transplanted# tissue# volume.# # Kanslets# do# provide# an# alternative# solution# to#
conventional# islet# transplantation.# Subsequent# studies# will# be# necessary# to#
determine# the# dosage# comparison# between# native# islets# and# Kanslets,# and# the#
marginal#mass#required#of#Kanslets#required#to#achieve#normoglycemia.#
# With#previous#studies#validating#the#superiority#of#small#islets#to#large#islets,#
there# was# a# shift# to# preferentially# utilizing# small# islets# for# both# research# and#
transplantation#[80,82I84].##However,#this#preference#leaves#significant#numbers#of#
large#islet#tissue#unused.#The#driving#force#behind#our#process#was#to#recreate#small#
islets# from# native# islet# cells# and# limit# islet# size# during# the# process.# # This# has#
implications# both# in# research# and# in# clinical# transplants.# # The# use# of# this# highly#
viable#tissue#in#transplantation#may#increase#overall#success#rates.##In#research,#the#
production#of#uniform# islet# tissue#allows# for# less#error#between# islet#preparations#























Native# small# islet# (A)# and# Kanslet# (B)# have# the# same# general# shape# and# are#
indistinguishable# under# light#microscopy.# (C)# Electron#micrograph# illustrates# that#











(A)#Kanslet#with#one#dead#cell#attached#to#the#side.# # It# is#clear#to#see#that#the#dead#
cell# is# outside# of# the# capsule# that# surrounds# the# reaggregated# islet.# # (B)# Kanslets#
have#significantly#greater#viability#when#compared#to#native#islets#within#24#hours#
of#isolation#or#removal#from#the#micromold.##All#values#are#expressed#as#the#average#
±# standard# error# (n# =# 510# Kanslets,# n# =# 86# native# islets),#p# <# .001,# *# =# statistical#











steady# state# conditions.# # (B)# In# contrast,# fluorescent# glucose# was# taken# up# by#
Kanslets# instantaneously# upon# introduction# to# the# medium.# # (C)# Analysis# of# the#















betaIcells# stained# for# insulin# (green),# alphaIcells# stained# for# glucagon# (red),# and#
deltaIcells# stained# for# somatostatin# (blue).# # (B)# The# overall# islet# cell# composition#



















to# varying# glucose# levels.# # Kanslets# were# exposed# to# low# glucose# (5# mM),# high#
glucose#(17.5#mM),#or#high#glucose#with#depolarization#(30#mM#K+).# #All#values#are#
expressed#as#the#average#±#standard#error#(n#=#10#replicates#from#4#rats),#p#<#0.05,#*#
=# significant# increase# in# insulin# secretion# when# compared# to# basal# glucose#
stimulation,#and###=#significant#increase#in#insulin#secretion#when#compared#to#high#
glucose#stimulation.#(B)#Kanslets#were#perifused#in#low#glucose#(3#mM),#followed#by#
exposure# to# high# glucose# (17.5#mM)# from#70# I# 130#minutes,#with# a# return# to# low#
glucose# for# the# remainder# of# the# study.# # A# spike# in# insulin# secretion#was# evident#








Native# islets# and# Kanslets#were# transplanted# into# streptozotocinIinduced# diabetic#
SD# rats# (2# rats#per#group).# #Rats# receiving# the# same#volume#of# either#native# islets#
(filled# circles)# or# Kanslets# (open# circles)# achieved# insulin# independence# and#
normoglycemia#for#the#2Iweek#period#following#transplant#with#blood#glucose#levels#












Millions# of# individuals# are# suffering# from# a# wide# variety# of# diseases# with#
cancer,#diabetes,#and#heart#disease#among#the#top#10#leading#causes#of#death#in#the#
United# States.# # Every# year,# research# efforts# are# being# focused# on# providing# better#
therapies#to#improve#the#quality#of#life#for#those#suffering#from#chronic#diseases.##As#
these# emerging# therapies# are# being# developed,# there# are# approaches# that# can# be#
improved# to# increase# productivity# and# success.# # One# of# the# major# transitions#
currently#benefiting# scientific#discovery,# is# a# shift# from#2D# to#3D# cell# culture.# # For#
decades,#researchers#have#utilized#2D#cell#culture#for#research#and#discovery.##With#
hopes# to# garner# insight# into# how# tissues# function# within# our# bodies,# the# flat#
morphology# of# 2D# cell# monolayers# lack# significance# and# can# provide# misleading#
results.# # Basing# our# understanding# of# cellular# systems# and# real# tissues# on# the# 2D#
system# comes# with# the# underlying# assumptions# that# cell# monolayers# mimic# true#
nature.##Unfortunately,#researchers#are#finding#that#this#is#not#the#case.##In#seeking#a#
more# physiologically# relevant# solution# for# in# vitro# testing,# researchers# are#
increasingly#transitioning#from#2D#to#3D#cell#culture.##
The# 3D# cell# culture# approach# is# a# hot# topic# right# now,#with# applications# in#
many#fields#including#basic#science,#drug#discovery#and#development,#regenerative#
medicine,# and# diagnostics.# # For# instance,# tumors# exist# as# spherical# structures#
composed#of#many#cell#types#working#together#in#a#complex#fashion#to#wreak#havoc#
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on# a# host’s# body.# # Cancer# researchers# have# observed# significant# differences#when#
utilizing#3D# tumor#spheroids# in#vitro# as#opposed# to#2D#cell#monolayers# [38,41,49I
51,121].# # In# the# case# of# lung# cancer# therapeutics,# a# study# found# that#most# of# the#
drugs#they#tested#in#a#2D#monolayer#environment#had#a#significantly#different#result#
on# the# same# cells# when# they# were# in# a# 3D# environment# [49].# # Using# 3D# tumor#
provides# researchers# with# the# best# solution# to# understand# tumor# biology# and#
discover#better#chemotherapeutics#for#treatments#and#cures.#
With# the# large# number# of# 3D# cell# culture# innovations# under# development,#
only# the# most# userIfriendly,# reproducible,# costIeffective# solutions# will# be# widely#
accepted#by# the#commercial#marketplace.# #The#entire#notion#behind# the#use#of#3D#
cell#culture#is#to#provide#support#for#cells#to#behave#in#a#natural#manner,#mimicking#
the#physiological#structure#within#living#systems.##A#wide#assortment#of#techniques#
are# being# utilized# to# engineer# tissues# in# a# scaffoldIfree# manner# [45,122].##
Spontaneous#cell# aggregation#and#selfIassembly#of#dispersed#cells,# a# foundation#of#
many# of# these# techniques,# has# been# a# phenomenon# extensively# studied# by#
researchers# [88,95,123I127].# # By# allowing# cells# to# aggregate,# albeit# in# an# in# vitro#
environment# under# controlled# conditions,# researchers# are# able# to# produce# tissueI
like#spheroids.#
When#developing#these#techniques#certain#criteria#to#consider#may# include:#
efficiency,# geometric# constraint,# influence# on# cell# physiology,# ease# of# use,# and#
scalability# for# commercial# applications# [125].# # Popular#methods# currently# utilized#
for# spheroid# formation# are# spinner# cell# culture,# the# hanging# drop# approach# and#




controlled# tissues# via# the#hanging#drop# approach#on# a# specially# designed#method.##
With# it,# comes# the# disadvantage# of# low# output,# evaporation,# and# small# volume#
medium# changes.# # # In# general,# many# of# the# technologies# are# being# designed# for#
specific# applications;#however,# a#universal#platform# technology# for#3D# cell# culture#
could#provide#greater#benefit#[45].#
In#developing#our#approach# to#3D#spheroid#production,#we#provide#a#novel#
platform#with# the# key# considerations# sought# out# by# the# commercial#marketplace.##
This# includes# providing# a# userIfriendly# tool# for# the# efficient,# scalable,# and# highI
output#production#of#3D#tissue#spheroids.##In#designing#our#method,#we#additionally#
considered#contamination,#culture#media#changes,#and#amount#of#manual#labor.##By#
incorporating# various# innovations# into# the# design,# we# provide# a# unique# platform#
that# is# simple# to# use,# applicable# for# high# content# screening,# allows# geometric# and#
size# control,# and# provides# a# low# cost# alternative# for# highIoutput# production.##
Although# initially# developed# for# application# to# diabetes# treatment# advancement# –#
diabetes#drug#development#and#transplantation,#we#have#expanded#the#use#of# this#
technology#in#several#other#applications.#
Our# technology# enables# gravityIenforced# aggregation# and# selfIassembly# of#
dispersed# cells# using# a# micromold# providing# geometric# constraints.# # The# surface#
contains#several#thousand#conicalIshaped#recesses#per#cm2,#specifically#tailored#for#
tissue# specific# requirements#or#by# the# researcher.# #The#micromolds#were#used# for#
the#production#of#isletIlike#spheroids#called#Kanslets.##In#this#study,#we#demonstrate#
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the# ability# to# use# Kanslets# for# drug# testing.# # Additionally,# we# discuss# how# we#





Glass# micromolds# were# fabricated# through# our# previously# discussed#
multistep# process# that# included# thinIfilm#metal# deposition,# photolithography,# and#
wet#chemical#etching.##Briefly,#glass#discs#were#cleaned#using#acid#and#base#piranha#
solutions#and#dried#at#200°C#to#remove#all#moisture.##Chromium#was#sputtered#onto#
one# surface#of# the#glass# substrate# (Lesker#Thin#Film#Deposition#System).# #Positive#
photoresist#(AZ1518)#was#spinIcoated#onto#the#chromium#surface#and#prebaked#at#
100°C# for# 2# minutes.# # A# transparency# mask# template,# designed# using# AutoICAD#










To# contain# culture# medium# and# cells# on# top# of# the# micromold,# a#









was# clamped.# # Via# the# common# bile# duct,# a# cannula# was# thread# in# situ# into# the#
pancreas.# # Cold# collagenase# (CLS1;# Worthington,# Lakewood,# NJ)# was# pumped,#







Before# engineering# islets# on# the#micromold,# isolated# islets# were# dispersed#
into# single# cell# suspensions.# # Islets# were# washed# twice# with# calciumI# and#
magnesiumIfree#HBSS#(cmfIHBSS).##Islets#were#then#incubated#on#a#rotator#at#37°C#
for# 20# minutes# in# cmfIHBSS# with# 4.8# mM# HEPES# and# papain# (5# units/ml;#
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Worthington,# Lakewood,#NJ).# # Islets#were# dispersed# by# trituration# using# a# pipette#





Established# lung# cancer# cell# lines# included# small# cell# lung# carcinoma# (NCII
H69),# epithelial# lung# carcinoma# (A549),# and# bronchioalveolar# carcinoma# (NCII
H358).##H69,#H358#were#originally#grown#in#RPMI#1640#media,#and#A549#was#grown#
in#Hams#F12K#media,#both# supplemented#with#10%# fetal#bovine# serum#(FBS)#and#




Bone# marrowIderived# mesenchymal# stem# cells# were# harvested# from# the#
femurs# of# exsanguinated# Sprague#Dawley# rats.# # Legs#were# completely# removed# at#
the#hip#joint#and#the#skin#and#foot#were#removed.##The#leg#bones#were#then#placed#in#
a# calciumI# and#magnesiumIfree# PBS# solution# for# 30#minutes.# # After# removing# the#
muscles,# the#femur#was#exposed#and#detached#at#the#knee.# #The#ends#of# the#femur#






treated# flasks# with# AlphaIMEM# containing# 10%# FBS# and# 1%# Anti/Anti.# # Culture#
medium#was#changed#carefully#every#24#hours#for#the#first#72#hours,#then#every#3I4#
days# until# they# reached# 70I90%# confluence.# # Aspirated# culture# medium# was#
discarded,#leaving#behind#BMSCs#that#had#adhered#to#the#flask#surface.#
When# ready# for# passaging# or# spheroid# production,# cells# were# trypsinized#
from#the#flask#surface#using#0.05%#trypsin/EGTA#(Gibco)#and#incubation#at#37°C#for#
5I10#minutes.# #The#cell#suspension#was#collected#from#the#flask#and#neutralized#by#
adding# complete# culture# medium# (containing# FBS).# # The# suspension# was# then#
pelleted# and# resuspended# in# fresh# culture# medium.# # If# passaged,# cells# were#
resuspended#in#AlphaMEMIbased#media,#split# into#two,#and#plated#into#new#flasks.##




Cryopreserved# HUMSCs# were# graciously# provided# by# Dr.# Omar# Aljitawi.##
Tubes#were#thawed#at#room#temperature#and#transferred#into#flasks#containing#low#
glucose# (5.5#mM)#DMEM#with# 20%#FBS# +# 1%#Anti/Anti.# # After# 24# hours# and# cell#
adherence,#culture#media#was#changed#to#low#glucose#DMEM#with#10%#FBS#and#1%#
anti/anti.# # Medium# was# changed# every# 48# hours# until# confluent.# # Cells# were#
trypsinized# using# the# previously# described# technique# for# passaging# or# spheroid#




To# produce# tissue# spheroids,# a# cell# suspension# was# loaded# onto# the#
micromold# surface#with# appropriate# culture#medium.# # In# the# case# of# hybrid# islets#
with# stem# cells,# cells# were#mixed# together# before# loading# onto#micromolds.# # The#
micromolds# were# incubated# at# 37°C# and# 5%# CO2.# # Culture# medium#was# changed#
every#24I48#hours.##After#5I10#days#(depending#on#tissue),#3D#tissue#spheroids#were#
removed# from# the# micromolds# by# washing# the# mold# several# times# with# culture#
media#and#collecting#the#suspension.##The#spheroid#containing#suspension#was#then#




Drug# doseIresponse# studies# were# completed# on# Kanslets# using# Byetta#
(exenatide;# Amylin# Pharmaceuticals)# and# another# known# stimulant# of# insulin#
secretion.# # Drugs# were# prepared# in# high# glucose# DMEM:F12Ibased# culture#media#
containing#17.5#mM#and#11.25#mM#glucose,#respectively.##Serial#dilutions#were#then#
completed# to# prepare# a# variety# of# doses,# with# no# addition# of# drug# as# a# control.##











digital# camera# or# an# Olympus# FluoView# 300# confocal# microscope# housed# at# the#
Diabetes#Research#Laboratory#at# the#University#of#Kansas#Medical#Center.# # Images#
were# acquired# at# 10I100X# and# analyzed# using# Olympus# FluoView# or# Lumenera#
Infinity#Software.#
Tissue# spheroids# were# assayed# for# viability# using# apoptotic# and# necrotic#
fluorophores# (propidium# iodide# and# YOIPROI1;# Vybrant# Apoptosis# Assay# Kit# #4,#







ability# to# leverage# the#micromold# technology# for#3D#culture#using#a#variety#of# cell#
types.# # In# previous# studies# we# have# produced# and# characterized# isletIlike# tissue#
spheroids,#or#Kanslets.##In#this#study,#using#a#similar#technique,#we#produced#cancer#
spheroids,# stem# cell# spheroids,# and# hybrid# islets# (containing# both# stem# cells# and#
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spheroids.# # Cancer# spheroids# can# be# made# monotypic# (composed# of# a# single# cell#
type)# or# heterotypic# (multiple# cell# types).# # Initially,# our# experiments# yielded# little#




cluster,# but#over# the#next# several#day#aggregation#period#grew# into# large# clusters.##
Compared#to#the#large#cluster#sizes#discussed#in#the#literature#(diameter#>#300#μm),#
these#clusters#measured#well#below#300#μm#and#remained#highly#viable#[48,129].#
Through# the# experiments,# we# found# that# although# cancer# spheroids# may#
initially#aggregate#less#than#100#μm#in#diameter,#after#removal#from#the#molds,#they#
expanded#during# cell# culture.# # It# appeared# that# cancer# cells# continued# to# replicate#
during#and#after#aggregate#formation.#Future#studies#are#necessary#to#determine#the#
appropriate#sizes#that#will#work#for#drug#testing#and#experimentation.##Additionally,#
cancerous# tumors# often# contain# hypoxic# or# necrotic# cores# that# release# a# lot# of#
chemical# factors# inducing# local#cell#death#[38,129].# #As#we#move#forward#with#this#
approach,#our#next# step#will# aim# to#produce#organotypic# cancer# spheroids.# #These#
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popular# [130].# # Stem# cells# are# generally# unspecialized# cells# that# maintain# their#
innate# ability# to# selfIrenew# or# proliferate# repeatedly,# but# can# differentiate# into# a#
variety# of# specialized# cells# under# the# appropriate# environmental# conditions,#
becoming# the# building# blocks# of# tissues# [130,131].# # Stem# cells# can# come# from# a#
variety#of#sources#including#embryonic#stem#cells,#induced#pluripotent#stem#cells,#or#
adult# stem#cells,# just# to#name#a# few.# #They# can#be#harvested# from#a#patient’s#own#
body#(autologous#stem#cells)#or#from#another#human#donor#(allogeneic).##Stem#cells#
are#already#being#used# clinically# for#bone#marrow# transplants.# #The#production#of#
stem#cell#spheroids#could#have#a#profound#impact#in#a#variety#of#fields.##For#example,#
it# could# provide# a# new# tissue# source# for# regenerative# medicine,# or# be# used# as# a#
platform#to#discover#new#drugs#that#aide#tissue#healing#and#growth.#
We#produced# two# types#of# stem#cell# spheroids#using#bone#marrowIderived#
mesenchymal# stem# cells# (BMSCs)# and# human# umbilical# cord# mesenchymal# stem#
cells# (HUMSCs)# (Figure#5.2).# #Our# studies#with# stem#cells#have#been# limited#so# far#
and# have# simply# been# conducted# to# demonstrate# stem# cell# spheroid# production#
using# the#micromolds.# # As#we#move# forward,# studies#will# include# the# use# of# stem#




In# diabetes# research,# the# limited# supply# of# donor# pancreata# places# a# large#
strain#on#advancing#islet#transplantation#as#a#cure#for#diabetes.# # Increasingly#more#
and#more,# researchers#are# looking# for# alternative# tissue# sources.# #A# recent# review#
discusses#the#potential#for#utilizing#stem#cells#as#an#alternative#source#[132].##




structure#or# the# inclusion#of# the#other# islet# cell# types# (alpha#cells,#delta# cells,# etc.)#
that#are#naturally#present#within#native#islets#[71I73,138].##Certainly,#this#work#is#on#
track# toward# providing# a# transplantable# alternative,# however# it# may# come# with#
unintended# situations.# # As# mentioned# previously,# stem# cells# maintain# the# innate#
ability#to#replicate#in#number.##Although#the#proliferation#pathways#may#be#stopped#
during# differentiation# into# isletIlike# cells,# this# may# not# always# be# the# case.##
Engineered#cell#lines#can#continue#to#maintain#some#oncogenic#characteristics#[66].##
In#any#case,#transplantation#of#transformed#stem#cell#can#have#cancerous#outcomes.#
Instead#of# transforming# stem#cells,# another#option#may#be# coItransplanting#
or#coIculturing#them#together#with#islets.##BMSCs#provide#beneficial#effects#for#islet#
coIculture# and# coItransplantation# including# protection# against# cell# damage#
increasing# islet# survival# and# function,# natural# transdifferentiation# into# isletIlike#
tissue,# and# supporting# angiogenesis# [132,139I142].# # More# specifically,# coI






islets# that# include# BMSCs# could# provide# another#method# for# the# incorporation# of#
stem# cells# into# islet# transplantation# settings.# #We# combined# BMSCs# and# islet# cells#
together# in# their#dissociated#state,# and#created#a#hybrid# islet#using# the#micromold#
(Figure#5.3).##In#a#quick#viability#assessment#it#appeared#that#coIaggregation#may#be#
beneficial# for# islet# survival# (Figure# 5.3B).# # Studies# are# to# be# conducted# to#
characterize# these# hybrid# islets# examining# properties# such# as# stem# cell#
transdifferentiation,#functionality,#and#transplantation#outcomes.#Hybrid#islets#could#
potentially# increase# the# amount# of# source# tissue,# while# providing# a# number# of#







involved# in#drug#development.# # The#key# in#developing# a# suitable#3D# cell# spheroid#
technology# is# the# inclusion# of# characteristics# such# as# size# uniformity,# normal# and#
uniform#drug#responses,#predictable#and#reliable#ED50s,#organotypic#structure,#low#
diffusion# barrier,# high# viability,# high# commercial# yield,# and# is# compatible# with#
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effect# on# insulinIsecretion# from# islets.# # Exenatide# (exendinI4),# a# glucagonIlike#
peptideI1#(GLP1)#analogue,#is#an#injectable#drug#used#to#enhance#glucoseIstimulated#




with# another# unnamed# drug# known# to# enhance# insulin# secretion# (Figure# 5.5).# # In#
ongoing#studies,#we#are#experimenting#with#the#effect#of#various#known#stimulatory#
and# inhibitory# compounds# on# Kanslets.# # These# studies# are# being# conducted# in#







This# innovative# solution# brings# physiological# relevance# to# traditional# cell# culture#
and#bridges#the#gap#between# in#vitro#experimentation#and#clinical#care.# #Building#a#
suitable# system# to# produce# 3D# tissue# spheroids# impacts# drug# discovery,#
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were# imaged# 4# days# after# removal# from# the# micromolds# (12# days# after# initial#
seeding#on#micromolds).##These#spheroids#remained#below#300#μm#and#maintained#




















These# hybrid# islets# are# composed# of# islet# cells# and# BMSCs# (AID).# # Fluorescent#































dates# quickly# approaching,# there# is# an# everIgrowing# need# for# technologies# that#
bridge# the# gap# between# in# vitro# experimentation# and# in# vivo# use.# # The# cells# and#
tissues# that# compose# organs# within# our# bodies# are# arranged# in# complex# 3D#
structures.# # It# is# less# than# ideal# to#use# traditional#2D#cell# culture# to#garner# insight#
and#make#inferences#about#topics#such#as#disease#states,#drug#action#mechanisms,#or#





within# isolated,# native# islets# prevent# them# from# use# as# a# viable# alternative.# # This#
calls#upon#engineering#an#optimal#isletIlike#spheroid.##
With#many#fields#only#beginning#to#make#a#transition#to#3D#cell#culture#in#the#
last# decade,# new# innovations# in# cell# culture# technology# are# gaining# popularity.##
Unfortunately,# these# technologies# and# techniques# come# with# inherent# caveats.##





optimized# size# by# limiting# tissue# aggregation# within# a# specific# size# range.# # These#
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isletIlike# spheroids,# or# Kanslets,# mimicked# the# structure# and# function# of# native#
islets.# # In# vitro,# Kanslets# were# highly# viable# and# maintained# glucose# sensitivity,#
insulin# secretory# response,# islet# morphology# and# structure.# # In# addition# to# the#
superior#viability,#the#reengineering#process#allowed#for#increased#diffusion#rates.##A#
preliminary# Kanslet# transplant# into# diabetic# rats# reversed# diabetes,# indicating#
similar#outcomes#as#native#islet#transplants.# #More#animal#studies#are#necessary#to#










similar#genetic# compositions.# #Using#a#donor#of# a#different# strain# compared# to# the#
recipient# may# offer# a# better# model# to# investigate# immunogenicity.# # One# possible#
solution#within#the#micromold#technology,#may#be#the#incorporation#of#stem#cells#to#
protect# Kanslets# or# hybrid# islets# from# graftIvsIhost# disease.# # Further#
characterization#of#hybrid#islets,#both#in#vitro#and#in#vivo#will#be#necessary.###




may# offer# better# dispensing# using# the# standard# industry# equipment.# # An# inIdepth#
analysis#is#necessary#to#provide#further#support#for#using#Kanslets#as#a#primary#and#
secondary#screening#tool#for#drug#discovery.###
Being# the# primary# tissue#model# in# this# research,# Kanslets# are# the# furthest#
along,#and#could#possibly#become#the#first#commercializable#product#to#come#out#of#
this# work.# # This# technology# in# not# only# applicable# for# diabetes# research.# # I# also#
produced# 3D# cell# spheroids# using# cancer# cells# and# stem# cells.# # Although# these#
experiments#were#preliminary,# they#explored# the#suitability#of# the#micromolds# for#
3D#cell#culture.# #With# industry# looking# for#simple,#highly#effective# technologies# for#
3D#cell# culture,# the# innovations#within# this# technology#enable#applications# in#drug#
discovery,#regenerative#medicine,#and#a#variety#of#other#fields.#
Giving#that#3D#cell#culture#is#just#beginning#to#catch#on,#as#we#think#about#the#
future#use#of# this#platform,#we#realize#that#we#have#only#scratched#the#surface.# # In#
addition# to# cancer# cells# and# stem#cell,# the#micromolding#process# could#work# for# a#
variety#of#other#cell#types.##For#example,#chondrogenic#and#osteogenic#cells#could#be#
optimally# aggregated,# providing# tissue# spheroid# building# blocks# for# a# variety# of#
regenerative# approaches.# # Using# a# variety# of# cell# types,# we# can# build# organotypic#
spheroids#with#applications# for#drug#testing#and#toxicology,#autologous#cancer#cell#
spheroids# for#personalized#medicine#and#diagnostics,# and# stem#cell# aggregates# for#
regenerative# medicine# approaches.# # This# technology# can# benefit# the# tissue#




During# the# process# of# engineering# islets,# it# is# important# to# provide#
appropriate#tissue#culture#medium#for#optimal#reaggregation.##Two#formulations#of#
tissue# culture# medium# was# developed# for# use# during# Kanslet# production:# a# drug#
testing#culture#medium#and#a#tissue#transplantation#culture#medium.##The#prepared#
culture#mediums#are#either#DMEM:F12Ibased#or#CMRL#1066Ibased.#
Tissue# culture# media# are# available# with# an# assortment# of# glucose#
concentration#varying# from#0# to#55#mM.# # Specific# concentrations#may#be# chose# to#
mimic#the#various#stages#of#blood#glucose#associated#with#diabetes.# #These#glucose#
concentrations# are:# 1# –# 5.5# mM# (low/normal/basal),# approaching# 10# mM# (preI
diabetic),# and# above# 10# mM# (high/diabetic).# # Commercially# available# DMEM:F12#
contains#17.5#mM#glucose.##Engineering#islets#at#this#high#glucose#level#is#analogous#
to# culturing# at# diabetic# blood# glucose# levels.# # To# eliminate# the# effects# of# this# high#
glucose#condition,#a#low#glucose#DMEM:F12#was#specifically#formulated#containing#
5#mM# glucose.# # A# 50:50#mix# of# no# glucose# DMEM# (0#mM# glucose)# is# mixed#with#
Ham’s#F12#(10#mM#glucose)#to#produce#a#DMEM:F12#combination#containing#5#mM#
glucose,# while# maintaining# similar# concentrations# of# the# other# additional#
components#contained#in#standard#DMEM:F12.##Commercially#available#CMRL#1066#
typically#contains#5.56#mM#glucose#and#was#left#unchanged.# #The#following#culture#








The# drug# testing#media# is# a# traditional# standard#media# formulation# and# is#
similar# to# that#which#we# have# used# in# previously# publications# [56,82].# # Our# drug#
testing# media# contains# 10%# (v/v)# fetal# bovine# serum# (FBS)# and# 1%# (v/v)#
antibiotic/antimycotic.##Specifically#for#our#CMRL#formulation,#we#included#2#mM#LI
glutamine#in#cases#where#CMRL#1066#was#purchased#without#glutamine.#




or# other# animal# products.# Serum# is# very# complex,# primarily# composed# of# serum#
albumin#and#growth#factors.##Additionally,#it#can#contain#proteins,#hormones,#amino#
acids,# and# other# components;# however,# the# effects# on# cell# culture# are# largely#
undetermined.# # The# components# in# our# transplantation# media# compensates# for#

















Our# transplantation# media# is# a# modified# version# based# on# a# formulation#
provided# by# Kikugawa,# et# al.# [146].# # Our# transplantation# media# uses# either#
DMEM:F12# or# CMRL# 1066# supplemented# with# BSA,# insulinItransferrinIselenium#
(ITS),# epidermal# growth# factor# (EGF),# exendinI4,# HEPES,# antibiotic/antimycotic.##
The# addition# of# BSA,# ITS,# EGF,# exendinI4# is# largely# based# on# the# formulation#
provided#by#Kikugawa,#et#al.#[146].#
In# developing# this# medium# we# experimented# with# the# addition# of#
nicotinamide#and#extra#calcium.##Nicotinamide#is#an#amide#of#nicotinic#acid#and#is#a#
part# of# the# vitamin# B# group.# # Many# research# groups# include# nicotinamide# in# the#
formulation#of#media#used#for#islet#cell#culture#to#aid#islet#isolation,#protect#against#
DNA#damage,#and#maintain#glucoseIstimulated#insulinIsecretion#[133,137,146I148].##
Nicotinamide,# also# known# as# niacinamide# is# found# as# a# component# of# DMEM:F12#
and#CMRL#1066.##A#recent#study#comparing#various#media#formulations#containing#
nicotinamide#found#that#the#standard#commercial#concentration#was#sufficient#and#
the# supplementation# of# additional# nicotinamide# (10# mM)# showed# no# beneficial#
effects#[149].# #Hence,#our#formulation#does#not#include#additional#supplementation#
of#nicotinamide.#
Initially,# we# experimented# with# addition# of# extra# calcium# (26# mM)# to# our#
culture#media#to#increase#cellItoIcell#adhesion.##Cells#can#naturally#maintain#calcium#





digestion,# the#cell#membrane#can#become#permeable#allowing# free# flow#of#calcium#
ions.# # The# extra# calcium# can# have# a# toxic# effect# on# cells.# # Immediately# upon#
reintroduction#of#calcium#to#the#media,#the#increased#influx#of#calcium#into#the#cells#
can#lead#to#toxic#calcium#levels#well#above#the#physiological#range.##Standard#media#
formulations# contain# calcium# in# a# low# millimolar# range# (0# –# 3# mM).# # In# our#
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